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1 Introduction 
1.1 Nestin discovery, classification and characteristics 
Nestin is an intermediate filament protein. It was first discovered in 1985 as an antigen, 
identified by Rat-401 monoclonal antibody, which is transiently expressed in 
neuroepithelial stem cells during development of central nervous system in rats 
(Hockfield and Mckay, 1985). Upon differentiation, nestin is replaced by other 
intermediate filament proteins specific for mature cells: by glial fibrillary acidic protein 
(GFAP) in glial cells and by neurofilament proteins in neurons (Lendahl et al., 1990; 
Messam et al., 2002). The name nestin comes from the location where it was 
discovered: neuroepithelial stem cell protein (Lendahl et al., 1990).  
After its discovery in neuroepithelial stem cells of rats, human (Dahlstrand et al., 1992) 
and mouse (Yang et al., 2001) nestin genes have also been characterized in detail. 
Intermediate filament family consists of around 60 – 70 proteins which are divided into 
six main types (type I – VI) on the basis of their molecular structure, nestin was 
classified as a type VI intermediate filament protein (Lendahl et al., 1990; Liem, 1993, 
Chang et al., 2004). 
Nestin is a 240 kDa protein with a short N-terminus and a very long C-terminus. Unlike 
other intermediate filaments, nestin is unable to polymerize by itself. This is due to the 
short N-terminal head domain which is essential for polymerization and assembly of 
filament proteins (Fuchs and Weber, 1994; Hermann and Aebi, 2000). Instead of self-
polymerization, nestin incorporates into the intermediate filament network by 
copolymerizing with various other intermediate proteins e.g. vimentin, desmin and α-
internexin (Sjöberg et al., 1994; Marvin et al., 1998; Eliasson et al., 1999 and Steinert et 
al., 1999). 
 
Introduction 
- - 11 - - 
1.2 Nestin as marker of stem/progenitor cells 
Nestin was initially described as marker of neural stem cells and neural progenitor cells 
(Cattaneo et al., 1990; Lendahl et al., 1990). In the meantime nestin was also observed 
in stem/progenitor cells of different tissues during embryonic development and repair or 
regeneration in adults (Wiese et al., 2004).  
Apart from nervous system, during embryonic development, nestin expression was 
detected in other tissues and organs which include skeletal muscles (Sejersen and 
Lendahl, 1993), hepatic cells (Sun and An, 2004), testis (Fröjdman et al., 1997; 
Davidoff et al., 2004), kidney (Chen et al., 2006), pancreas (Aihara et al., 2004), heart 
(Kachinsky, 1995), teeth (About et al., 2000) and retina (Dore-Duffy et al., 2006). 
In adults, nestin expressing cells are restricted to defined locations/niches where they 
may serve as a progenitor cell population capable of proliferation, differentiation and 
migration, when activated (Wiese et al., 2004). Nestin in adults is reported to be 
expressed in hair follicle cells (Li et al., 2003; Amoh et al., 2004), blood vessels 
between hair follicles (Aki et al., 2010), skeletal muscle cells (Birbrair et al., 2011), 
vascular smooth muscle cells and pericytes (Davidoff et al., 2004), cardiac progenitor 
cells (Calderone, 2011), skin (Toma et al., 2001) and retina (Mayer et al., 2003). 
In recent years, nestin expression has also been found in tumors from different origins 
(see Krupkova et al., 2010) with suggested role in tumor angiogenesis (Shimizu et al., 
2006; Teranishi et al., 2007; Gravdal et al., 2009; Chen et al., 2010; Ishiwata et al., 
2011). Some studies have even described nestin as prognostic marker of progression of 
certain tumors and poorer survival probability for patients (Ehrmann et al., 2005; Ryuge 
et al., 2011).  
1.3 Nestin in vascular wall 
Some studies also show that nestin+ cells are located in vascular walls representing the 
progenitor cell populations for different tissues. Different cell types in vascular wall e.g. 
endothelial cells, vascular smooth muscle cells and pericytes etc. were suggested to 
express nestin under certain conditions. In one previous study from our group, we have 
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already demonstrated nestin+ vascular smooth muscle cells and pericytes as progenitors 
of testosterone producing Leydig cells (Davidoff et al., 2004).  
Vascular wall resident progenitor cells have been described in different cell populations 
of lung (Beers and Morrisey, 2011; Yeager et al., 2011) but there is virtually no data on 
expression and localization of nestin in the lung, during both pre- and postnatal 
development and repair. 
1.4 Lung development 
Lung consists of two highly branched, tree-like tubular systems, the airways and the 
vasculature which develop in a well-coordinated way starting from the primary lung 
bud to the generation of millions of alveoli. Both the airways and vascular systems 
allow lung to fulfill major function of gas exchange between air and tissue deep within 
an animal (Warburton, 2008; Morrisey and Hogan, 2010; Warburton et al., 2010).  
1.4.1 Bronchial tree and branching system  
Bronchial tree starts from trachea which bifurcates into segmental bronchi containing 
cartilage plates. Each bronchus further divides to form large and small sub-segmental 
bronchi. A small segmental bronchus is continuous with the bronchiole and the 
differences involve loss of cartilage plates and increase in number of elastic fibers. The 
terminal bronchiole give rise to further branches called respiratory bronchioles that end 
up into alveoli (Kierszenbaum, 2007). Branching morphogenesis of lung epithelium has 
been studied in different species. Morphometric analysis of mice lungs fixed at different 
embryonic time periods present a simple explanation of branching morphogenesis 
during development. The branching pattern can be divided into three geometrical modes 
that include domain branching, planer bifurcation and orthogonal bifurcation (Metzger 
et al., 2008).  
1.4.2 Vascular tree and vascular system  
In general the vascular tree is composed of three different types of blood vessels; 
arteries, capillaries and veins. The vascular system of lung consists of two circulations; 
bronchial circulation and pulmonary circulation. The bronchial circulation carries 
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systemic blood to walls of airways and large vessels and provides nutrients and oxygen 
while the pulmonary system is responsible for gas exchange at alveolo-capillary level. 
The pulmonary circulation is further classified into proximal and peripheral vasculature. 
Proximal vasculature consists of large, medium and small pulmonary arteries while 
peripheral vasculature is comprised of small non-muscular arteries and capillaries 
(Stenmark and Abman, 2005). Two different processes are involved in development of 
blood vessels; vasculogenesis and angiogenesis. Vasculogenesis is the process in which 
endothelial progenitor cells (angioblasts) are recruited that differentiates into mature 
endothelial cells that form blood vessels. On the other hand angiogenesis is defined as 
process where new vessels arise by sprouting from pre-existing vessels (Gao and Raj, 
2010). 
1.4.3 Different stages of lung development 
In mammals, lung develops quite late during gestation. The earliest signs of primary 
lung buds appear at about 28 days in humans and at E9.5 in mouse (Morrisey and 
Hogan, 2010). Lung development can be divided into five stages on the basis of 
histological evidence; 
1. Embryonic stage 
2. Pseudoglandular stage 
3. Canalicular stage 
4. Saccular stage 
5. Alveolar stage 
The exact timing of different developmental stages varies in different species. The 
marsupials are born with the lungs in canalicular or saccular stage while, in sheep, lungs 
are already alveolarized at birth. In newborn humans, lungs contain only a fraction of 
adult alveoli and the capillary network is also immature. The rat lung is even less 
mature than human lung at birth (Burri, 2006). 
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Fig. 1: Lung development: The developmental stages of lung are illustrated in 
chronological order showing comparison of time periods for each developmental stage 
between mouse lung and human lung (modified from Warburton et al., 2006). 
The pulmonary vascular development and branching morphogenesis of airway system 
occur simultaneously. In embryonic stage the primary lung bud appears as ventral 
diverticulum of the foregut which divides to form two lung buds (Hislop, 2002). The 
most proximal part of pulmonary circulation is derived from the Tr. arteriosus which 
divides into the aorta and pulmonary trunk. At this stage, blood supply to the lung buds 
is through pulmonary artery coming from outflow tract of heart running alongside 
trachea and into the lung bud. On the ventral side of lung buds, there is a pulmonary 
vein that connects with prospective left atrium and between the arteries and veins; there 
is a plexus of capillaries around the lung buds. (Hall et al., 2000; Hall et al., 2002) 
In pseudoglandular stage, the lung buds divide to form pre-acinar airways and at the 
same time pulmonary macrovasculature (arteries and veins) and microvasculature 
(capillaries) are formed independently and are connected to each other (deMello et al., 
1997; deMello and Reid 2000). 
During canalicular stage, further divisions of pre-acinar airways take place resulting in 
the formation of respiratory airways. This developmental stage is associated with 
marked increase of capillaries which are arranged in close apposition to the epithelium 
establishing the first air-blood barrier (Gao and Raj, 2010).  
During saccular stage, the airways end up into clusters of thin walled air spaces called 
saccules. The saccules are separated from each other by primitive inter-saccular septae 
which contain a double layer of capillaries (Gao and Raj, 2010).  
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The last phase of lung development is the alveolar stage which is a post-natal event in 
most of the mammals. During the period of alveolarization, the inter-alveolar septae 
become thin, the microvasculature undergoes remodeling as the double layer capillary 
network regresses and transforms into a single layer adult type (Burri, 2006).  
It is quite unclear when the alveolar stage ends. In classical view, the alveolar stage 
ends at 2 years in humans but recent studies in mice (Mund et al., 2008), rats (Schittny 
et al., 2008) and monkeys (Hyde et al., 2007) suggest that alveolarization does not stop 
until young adulthood. 
1.5 Pulmonary hypertension 
Pulmonary hypertension is a fatal disease characterized by pulmonary vascular 
remodeling resulting into progressive and sustained elevation of pulmonary arterial 
pressure and increased pulmonary vascular resistance eventually causing right heart 
failure and premature death (Humbert et al., 2004; Hoendermis, 2011).  
Hemodynamically, pulmonary hypertension in man is defined as a mean pulmonary 
arterial pressure (PAP) greater than 25 mmHg at rest or greater than 30 mmHg with 
exercise by right heart catheterization (Gaine and Rubin, 1997). 
Pulmonary hypertension was initially classified as primary or secondary pulmonary 
hypertension (Hatano and Strasser, 1975; Rubin, 1997) during first pulmonary 
hypertension meeting at world health organization symposium in 1973. In second world 
symposium on pulmonary hypertension held in Evian, France in 1998, a new 
classification was introduced. The Evian classification categorized pulmonary 
hypertension into five groups on the basis of shared clinical and pathological features as 
well as similar therapeutic options (Fishman, 2001).  
1. Pulmonary arterial hypertension 
2. Pulmonary venous hypertension 
3. Pulmonary hypertension associated with disorders of the respiratory system or 
hypoxemia 
4. Pulmonary hypertension caused by thrombotic or embolic diseases 
5. Pulmonary hypertension caused by diseases affecting the pulmonary vasculature 
 
Introduction 
- - 16 - - 
This classification was reviewed in third world symposium on pulmonary hypertension 
in 2003 and modest changes were made. The current classification of pulmonary 
hypertension was formulated in 2008 during 4th world symposium on pulmonary 
hypertension held in Dana Point, California, USA. In this classification, the general 
philosophy and organization of Evian-Venice classifications is maintained but some 
modifications were made (Simonneau et al., 2009). According to Dana Point 
classification, the five major categories of pulmonary hypertension are; 
1. Pulmonary arterial hypertension 
2. Pulmonary hypertension owing to left heart disease 
3. Pulmonary hypertension owing to lung diseases and/or hypoxia 
4. Chronic thromboembolic pulmonary hypertension 
5. Pulmonary hypertension with unclear multifactorial mechanisms 
The pathogenesis of pulmonary hypertension is a very complex process. The main 
players in progression of pulmonary hypertension involve; pulmonary vasoconstriction, 
structural remodeling of pulmonary vessel wall and thrombosis (Mandegar et al., 2004). 
In recent years, the fact has been established that vascular remodeling is the hallmark of 
pulmonary hypertension pathogenesis (Yeager et al., 2011). Under physiological 
conditions, the thickness of vessel wall is maintained at an optimal level by establishing 
a balance between proliferation and apoptosis of resident cell types. When this balance 
is disturbed in favor of proliferation, the vascular wall thickens narrowing the vessel 
lumen and resulting in increased resistance. This structural change of vessels is referred 
to as vascular remodeling (Kato and Staub, 1966). Pulmonary vascular wall consists of 
three layers; intima containing endothelial cells, media harboring smooth muscle cells 
and the third is adventitia whose cellular components are fibroblasts. All the three 
cellular layers are involved in the complicated process of vascular remodeling 
(Mandegar et al., 2004; McGrath et al., 2005; Chan and Loscalzo, 2008; Yeager et al., 
2011) by means of hypertrophy (cell growth) and/or hyperplasia (proliferation) of 
smooth muscle cells, signal transduction from neighboring fibroblasts and endothelial 
cells, as well as increased deposition of extracellular matrix components including 
collagen, elastin, and fibronectin (Jeffery and Wanstall, 2001). 
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1.6 Models to study pulmonary hypertension 
Huge amount of research is going on in the field of pulmonary hypertension. There are a 
number of animal models used to study pulmonary hypertension. These animal models 
have provided, and will continue to provide, valuable insight into the numerous 
mechanisms and pathways that contribute to the pathogenesis and maintenance of 
pulmonary hypertension allowing us to develop novel therapeutic strategies. The best 
described and most frequently used models include hypoxia induced pulmonary 
hypertension in rodents (rat and mouse) and monocrotaline (MCT) induced pulmonary 
hypertension in rats (Pak et al., 2007; Stenmark et al., 2009). 
1.6.1 Hypoxia induced pulmonary hypertension 
Hypoxia is the most commonly used model to study vascular remodeling because it is 
very much predictable and reproducible within a specific species, however, response to 
hypoxia varies in different species. The effect of hypoxia has been studied in many 
animals but the most commonly used hypoxic animal systems are those of rat and 
mouse (Stenmark et al., 2009). Hypoxia is a more physiological model as compared to 
any other model as it occurs in nature as a pathological stimulus leading to development 
of pulmonary hypertension at high altitude or as consequence of hypoxic lung disease at 
sea level (Pak et al., 2007).  
In this model, animals are exposed to hypoxic conditions (≤ 10% O2) for 3 weeks. 
During this time period they develop pulmonary hypertension which can be confirmed 
by hemodynamic measurements as well as histological observations. Hypoxia-induced 
pulmonary hypertension is associated with very similar structural changes in almost all 
mammals investigated so far; however, the magnitude of these changes may differ in 
different animals.  
Thickening of media occurs consistently in the arteries at all levels of the pulmonary 
tree. There is extension of smooth muscle cells in small, normally nonmuscular 
arterioles that is obvious by increase in the appearance of cells expressing α-smooth 
muscle actin in the walls of previously nonmuscular arterioles. This process is called 
muscularization (Sakao et al., 2009; Stenmark et al., 2009). These changes were 
suggested to be due to differentiation of precursor pericytes and intermediate cells into 
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smooth muscle cells (Meyrick and Ried, 1980). Intermediate cells were defined as 
intermediates between pericytes and smooth muscle cells. Other suggestions include 
recruitment and differentiation of fibroblasts and circulating mononuclear progenitor 
cells into smooth muscle cells (Jones et al., 1999) and transdifferentiation of endothelial 
cells into mesenchymal cells (Sakao et al., 2009). Simultaneously, there is also increase 
in thickness of previously muscularized arteries which is the result of both smooth 
muscle cell proliferation and hypertrophy (Meyrick and Perkett, 1989; Stenmark et al., 
2009).  
After exposure to hypoxia, mice also show increase in pulmonary arterial pressure but 
pulmonary hypertension in mice is associated with less degree of vascular remodeling 
as compared to other animals e.g. rats. In mice, major changes include muscularization 
of previously non-muscularized arterioles and minimal medial thickening in muscular 
arteries where increased proliferation of smooth muscle cells is observed (Stenmark et 
al., 2009). The exact mechanisms and cell types involved in hypoxia induced vascular 
changes are still unclear. 
On returning to normoxic atmosphere the experimental hypoxia induced pulmonary 
hypertension is reversed and after certain recovery periods, pulmonary arterial pressure 
comes to normal. In addition vessel walls regain their original thickness, whereas, the 
amount of collagen fibers increases (Meyrick and Ried, 1980; Marsboom & Janssens, 
2004). 
1.6.2 Monocrotaline model of pulmonary hypertension 
Monocrotaline (MCT) is a plant derived toxin extracted from seeds of Crotalaria 
spectabilis. A single subcutaneous or intraperitonial injection of monocrotaline results 
in progressive pulmonary hypertension in different species. The preferred species to 
study monocrotaline induced pulmonary hypertension is rat, while mice show variable 
results after monocrotaline administration (Stenmark et al., 2009). In vivo, 
monocrotaline is activated by mixed function oxidases in liver to form bifunctional 
cross-linking compound MCT pyrrole which is transported to lungs where it causes 
vascular injury resulting into pulmonary hypertension (Marsboom & Janssens, 2004; 
Stenmark et al., 2009; Gomez-Arroyo et al., 2011).  
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Like hypoxia, monocrotaline induced pulmonary hypertension is also characterized by 
vascular remodeling. The exact mechanism by which monocrotaline causes vascular 
remodeling is not known. It is assumed by many investigators that monocrotaline causes 
endothelial damage which triggers smooth muscle cell proliferation and/or endothelial 
cell mesenchymal transition. Other investigators suggest that vascular remodeling and 
increase in pulmonary artery pressure is caused by early and dramatic accumulation of 
mononuclear inflammatory cells in adventitia of small intra-acinar vessels (Stenmark et 
al., 2009). The mechanism explaining the processes between early endothelial injury 
and medial hypertrophy is still missing. The monocrotaline rat model continues to be a 
frequently investigated model of pulmonary hypertension as it offers technical 
simplicity, reproducibility and low cost compared to other models of pulmonary 
hypertension (Gomez-Arroyo et al., 2011).  
1.6.3 Su5416/hypoxia model for pulmonary hypertension 
Hypoxia in combination with VEGF receptor-2 (VEGFR-2) inhibition by VEGFR-2 
antagonist Sugen 5416 results in severe pulmonary hypertension (Taraseviciene-Stewart 
et al., 2001; Sakao et al., 2005) and is used as model to study experimental pulmonary 
hypertension (see also 1.7.2). In general, this animal model quite resembles the 
traditional monocrotaline model of pulmonary hypertension with prominent 
perivascular inflammatory infiltrates (Stenmark et al., 2009). The salient feature of this 
animal model is that animal treated with Su5416 and hypoxia develops certain 
characteristic vascular lesions found in human pulmonary hypertension (Abe et al., 
2010). VEGF is an important survival factor and endothelial cells undergo apoptosis 
when deprived of VEGF (Gerber et al., 1998) or are exposed to VEGF-2 inhibitor 
(Kasahara et al., 2000; Taraseviciene-Stewart et al., 2001). In the Su5416/hypoxia 
model VEGFR-2 blockade is assumed to result in endothelial cell apoptosis which is 
followed by hypoxia induced proliferation of vascular smooth muscle cells and 
apoptosis-resistant endothelial cells (Taraseviciene-Stewart et al., 2001). It is still 
unclear whether proliferating endothelial cells contribute to formation of neointima or 
these are the vascular smooth muscle cells that proliferate and migrate into intima. 
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1.7 Molecular mediators of vascular remodeling in pulmonary 
hypertension 
1.7.1 Vasoactive mediators 
Pulmonary hypertension is characterized by imbalance in vasoactive mediators. In 
patients with pulmonary hypertension the production of vasodilators like nitric oxide 
(NO) and prostacyclin/prostaglandin I-2 (PGI2) is reduced (see Schermuly et al., 2011). 
Nitric oxide is a potent vasodilator. It is synthesized by endothelial cells of the vessel 
wall, by endothelial NO synthase (eNOS). NO exerts its vasodilatory effect on smooth 
muscle cells with the help of guanylate cyclase/cyclic guanosine monophosphate 
(cGMP) pathway. 
Prostacyclin is also a strong vasodilator produced by endothelial cells. Prostacyclin 
acts on adenylate cyclase that induces the synthesis of cyclic adenosine monophosphate 
(cAMP) and finally smooth muscle cell relaxation. PGI2 receptor knockout mice 
develop severe hypoxia induced pulmonary hypertension (Hoshikawa et al., 2001) 
while PGI2 over expressing mice do not develop pulmonary hypertension (Geraci et al., 
1999) suggesting some significant role of prostacyclin in pathogenesis of pulmonary 
hypertension. 
Both NO and prostacyclin possess anti-proliferative properties (Jeffery & Wanstall, 
2001) and reduction in their generation may contribute to increased proliferation of 
smooth muscle cells or fibroblasts during pulmonary hypertension. 
In contrast to vasodilators, the generation of vasoconstrictors like endothelin-1, 
thromboxane and serotonin (5-hydroxytryptamine 5-HT) is increased in patients with 
pulmonary hypertension (see Schermuly et al., 2011). 
Endothelin-1 is a potent vasoconstrictor produced by vascular endothelial cells. Two 
different Endothelin-1 receptors, ETA and ETB, are present on smooth muscle cells 
which mediate vasoconstriction (Rabinovitch, 2008). Endothelin also stimulates 
proliferation of smooth muscle cells through downstream signaling pathways of ETA 
and ETB receptors (Davie et al., 2002). 
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Thromboxane is another vasoconstrictor produced by pulmonary endothelial cells and 
platelets. Along with vasoconstriction, it induces aggregation of platelets as well as 
proliferation of pulmonary artery smooth muscle cells (Fischer et al., 2000). 
Serotonin, like ET-1 and thromboxane, also shows both vasoconstrictive and 
proliferative effects on smooth muscle cells. The vasoconstriction is mediated by 5-HT 
receptors 1B, 2A and 2B (MacLean et al., 2000) while serotonin stimulates smooth 
muscle cell proliferation via 5-HT transporter mediated uptake of serotonin (Eddahibi et 
al., 2006). The inhibition of 5-HT transporter inhibition reversed monocrotaline-induced 
PH in rats (Guignabert et al., 2005) suggesting the role of serotonin in proliferation of 
smooth muscle cells. 
Variations in both K+ and Ca2+ ion channels are associated with pathological vascular 
tone, disturbance of cellular homeostasis and induction of fibroproliferative action 
especially in smooth muscle cells.  
The classic function of K+ channels is regulation of vascular tone and membrane 
potential but in recent years, K+ channels expressed by smooth muscle cells were 
suggested to take part in vascular remodeling by regulating proliferation and apoptosis 
(Moudgil et al., 2006; Burg et al., 2008). Sustained Ca2+ flux into the cells also exerts 
mitogenic effects on smooth muscle cells. This effect is produced via Ca2+-calmodulin 
dependent stimulation of cell cycle and activation of mitogen induced protein kinase 
pathways upstream of several growth factors (Burg et al., 2008). 
Ca2+ signaling via transient receptor potential ion channels (TRPC) has significant role 
in pulmonary hypertension. TRPC3 and TRPC6 were found to be up-regulated in 
patients of pulmonary hypertension while the inhibition of TRPC6 expression 
significantly reduced smooth muscle cell proliferation (Yu et al., 2004; Weissmann et 
al., 2006). 
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1.7.2 Pro-proliferative mediators 
Apart from proliferative actions of certain vasoconstrictors, a number of pro-
proliferative signaling pathways have been identified in the pathophysiology of 
pulmonary hypertension (see Schermuly et al., 2011). 
Several growth factors are implicated in pulmonary hypertension and vascular 
remodeling. Growth factors act as potent mitogens and chemoattractants for vascular 
cells such as smooth muscle cells, fibroblasts, and endothelial cells by binding and 
activating cell surface tyrosine kinase receptors. Activation of the tyrosine kinase 
receptor initiates major intracellular signaling cascades, resulting in cellular 
proliferation, migration, and resistance to apoptosis (see Schermuly et al., 2011).  
Vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR-2) are 
expressed in the plexiform lesions of patients suffering from pulmonary hypertension 
suggesting a complex role for VEGF in the pathogenesis of pulmonary hypertension 
(Tuder & Yun, 2008). VEGF is up-regulated in rats with hypoxic treatment but down-
regulated in MCT treated rats (Partovian et al., 1998a; Partovian et al., 1998b). 
Hypoxia, in combination with inhibition of VEGF receptor inhibition using VEGF 
receptor antagonist Su5416, results in severe pulmonary hypertension (Taraseviciene-
Stewart et al., 2001). 
Platelet derived growth factor (PDGF) signaling is implicated in many proliferative 
diseases. Many investigations suggest that platelet derived growth factor B promotes 
proliferation and migration of vascular smooth muscle cells and may play a role in the 
progression of pulmonary hypertension. The upregulated expressions of PDGF-BB 
homodimer and its receptor PDGF-Rβ is correlated with pulmonary hypertension in 
various animal models (Schermuly et al., 2005; Andrae et al., 2008; Li et al., 2010; 
Dahal et al., 2011) and in humans (Schermuly et al., 2005; Perros et al., 2008). Hypoxia 
is reported to regulate arterial smooth muscle cell proliferation in a paracrine manner 
via PDGFR-β as under hypoxic conditions, arterial endothelial cells are shown to 
secrete PDGF-BB that stimulates smooth muscle cell proliferation via PDGFR-β 
expression in vivo (Chanakira et al., 2012). PDGF receptors belong to the family of 
transmembrane receptor kinases. Treatment with the PDGF receptor antagonist Imatinib 
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which is an inhibitor of receptor tyrosine kinases (Hossein et al., 2006) resulted in 
reverse remodeling of vasculature in two animal models of pulmonary hypertension that 
include monocrotaline treated rat model and hypoxia treated mouse model (Schermuly 
et al., 2005). However, the activation of PDGF and its receptors during the course of 
pulmonary hypertension in association with nestin expression and vascular smooth 
muscle cell proliferation still needs to be investigated. 
Fibroblast growth factor (FGF) is also up-regulated during vascular remodeling. Up-
regulation of basic fibroblast growth factor (bFGF) occurs in vascular smooth muscle 
cells of rats exposed to hypoxia while FGF-2 is up-regulated in lambs with pulmonary 
hypertension (Li et al., 2003; Wedgwood et al., 2007; Schermuly et al., 2011). 
Inhibition of FGF-1 receptor causes reversal of established pulmonary hypertension 
(Izikki et al., 2009). 
Transforming growth factor alpha (TGF-α) is a member of the epidermal growth 
factor (EGF) family. Over expression of TGF-α results in development of pulmonary 
hypertension and might be correlated with EGF-induced proliferation of smooth muscle 
cells in pulmonary vasculature (Le Cras et al., 2003). 
TGF-β superfamily regulates many cellular functions including proliferation, migration, 
differentiation and secretion and deposition of extracellular matrix. TGF-β signaling is 
also implicated in the progression of pulmonary hypertension. Alterations in TGF-β 
signaling pathways, via bone morphogenic protein receptor 2 (BMPR-2) and TGF-β 
receptor 1, are associated with pathogenesis of pulmonary hypertension. In majority of 
patients suffering from heritable pulmonary hypertension, mutations have been found in 
BMPR2 gene suggesting a strong role of BMPR2/TGF-β signaling in pathogenesis of 
pulmonary hypertension (Machado et al., 2009). 
Notch signaling is involved in vasculogenesis, angiogenesis and differentiation of 
vascular smooth muscle cells (Alva et al., 2004). Notch3 is an important mediator 
supposed to be involved in pulmonary hypertension by promoting proliferation of 
vascular smooth muscle cells (Campos et al., 2002). Notch 3 is also known to regulate 
the expression of PDGF receptor β in vascular smooth muscle cells (Jin et al., 2008). 
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1.8 Progenitor cells in pulmonary vasculature 
Repair, remodeling and regeneration of the respiratory system for maintenance of 
homeostasis of lung after injury have been one of the main focuses of pulmonary 
biologists in recent years. Like other externally exposed organs e.g. skin, lung is also 
confronted by various insults and injuries and the occurrence of a complex spatial 
organization and variety of cell types that form the mature organ, suggest that multiple 
pools of multipotent stem/progenitor cells capable of self-renewal are required for 
repair, remodeling or regeneration after injury (Beers and Morrisey, 2011). 
Traditionally, the cell components of the vessel walls are thought to be mature and 
terminally differentiated (Psaltis et al., 2011). Until the last decade, angiogenesis, 
formation of new vessels from pre-existing vessels, was considered to be the only 
process for the formation of new blood vessels (Carmeliet, 2003).  
In recent years, the traditional view has been revised due to discoveries of diverse 
stem/progenitor cells relevant to cell types in the vessel wall which include endothelial 
cells, vascular smooth muscle cells, pericytes and fibroblasts (Stenmark et al., 2006; 
Pearson, 2010; Crisan et al., 2011; Majesky et al., 2011). Significant amount of 
evidence indicate that these different stem/progenitor cells exist within the vessel wall, 
where they may reside permanently, or appear as the result of migration (Psaltis et al., 
2011). 
1.8.1 Circulating progenitor cells 
Endothelial progenitor cells are the most studied adult progenitor cells in recent years. 
Endothelial progenitor cells were first discovered by Asahara et al. in 1997 where they 
were shown to be recruited to the sites of active angiogenesis in adults (Asahara et al., 
1997). Endothelial progenitor cells are thought to derive from bone marrow and 
circulate in the peripheral blood. Most frequently used marker proteins to identify 
endothelial progenitor cells include vascular endothelial growth factor receptor-2 
(VEGFR-2), mucosialin (CD34), prominin-1 (CD133) and c-kit (CD117; the receptor 
for stem cell factor) (Timmermans et al., 2009). 
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Circulating smooth muscle progenitor cells were also reported to contribute to vascular 
remodeling (Daniel and Sedding, 2011) but this progenitor cell population is not so 
intensively studied as endothelial progenitor cells. Circulating smooth muscle 
progenitor cells are also reported to originate from bone marrow and can be found in 
circulating blood or peripheral tissues. They can be identified by using certain marker 
proteins which include endoglin (CD105), α-smooth muscle actin (α-SMA), calponin, 
smooth muscle myosin heavy chain and platelet derived growth factor receptor-β 
(Simper et al., 2002; Sugiyama et al., 2006). 
Another potential vascular progenitor cell type that has got attention in recent years is 
the fibrocyte. “Fibrocytes” are bone marrow derived mesenchymal progenitor cells 
which migrate to the region of injured tissue. These cells can be distinguished by the 
expression of hematopoietic and monocyte lineage markers and extracellular matrix 
proteins (Grieb et al., 2011). Fibrocytes are also implicated in pulmonary hypertension 
(Gambaryan et al., 2012). 
1.8.2 Vessel wall resident progenitor cells 
Along with the circulating progenitor cells, recent findings from studies on human 
tissues and in vivo studies in animal models confirm the presence of progenitor and 
stem cells in vessel wall. It is not investigated whether a putative stem/progenitor cell 
population exists in vessel wall which is capable of differentiating to all types of cells 
but there is increasing evidence of different types of stem/progenitors cells within the 
vessel wall capable of differentiating into mature vascular wall cells (Klein et al., 2010; 
Psaltis et al., 2011; Torsney and Xu, 2011; Yeager et al., 2011).  
Although typically thought to originate from bone marrow, it is now reported that 
endothelial progenitor cells can also arise locally within various tissues, including the 
vascular wall (Tilki et al., 2009). The localization of endothelial progenitor cells in 
vessel wall was identified in sub-endothelial space and in the so-called vasculogenic 
zone in the tunica adventitia (Zengin et al., 2006). 
Similarly, smooth muscle progenitor cells can also reside within the vessel wall. One 
possible niche is tunica intima, where certain mature endothelial cells can give rise to 
smooth muscle cells via endothelial-mesenchymal transdifferentiation (Frid et al., 
 
Introduction 
- - 26 - - 
2002). Another cell population capable of differentiating into smooth muscle cells 
identified by stem cell antigen-1 (Sca-1) was found to reside in the vasculogenic zone at 
the border of media and adventitia (Hu et al., 2004; Passman et al., 2008).  
Mesenchymal stem cells are present in almost all organs and recent data suggest that 
mesenchymal stem cells also reside in certain niches within the vessel wall e.g. sub-
endothelial space and adventitia (da Silva et al., 2006; Zengin et al., 2006). 
Mesenchymal stem cells are thought to be closely related with pericytes (Caplan, 2008; 
Kovacic et al., 2009). Both pericytes and mesenchymal stem cells have been assigned 
similar niches, predominantly perivascular region, in various tissues and both cell types 
also express common cell markers like CD44, CD90, CD105, stromal precursor 
antigen-1 (STRO-1), neural glial antigen-2 (NG2), alkaline phospatase, α-smooth 
muscle actin (α-SMA) and platelet derived growth factor receptor-β (PDGFR-β) (Psaltis 
et al., 2011). The presence of pericytes and/or mesenchymal stem cells throughout the 
vasculature suggests these cells as progenitors of a variety of cell types (Kovacic et al., 
2009). 
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1.9 Nestin+ resident progenitor cells in the vessel wall 
In a previous study from our group we found that nestin expressing vascular smooth 
muscle cells and pericytes in testicular blood vessels are the progenitors of testosterone 
producing Leydig cells (Davidoff et al., 2004). Here we demonstrated that vascular 
smooth muscle cells and pericytes in peri-tubular blood vessels express nestin. These 
nestin expressing cells proliferate and protrude out of blood vessel and transdifferentiate 
into Leydig cells. 
The question was that whether these nestin expressing progenitor cells also occur in 
other organs? To answer this, our colleague Claudia Berndt investigated nestin 
expression in lungs using nestin-GFP transgenic mice and found nestin expression in 
pulmonary vessels. Nestin was predominantly found in arteries while veins and 
capillaries also showed nestin expression. Using cell specific markers (α-SMA for 
smooth muscle cells and CD31 for endothelial cells), she was able to characterize nestin 
expressing cells as vascular smooth muscle cells (Fig. 2). Nestin was only found in 
vascular smooth muscle cells while smooth muscle cells around the airways were 
negative for nestin which is clearly visible in staining of nestin-GFP sections with 
smooth muscle actin (Fig. 2A) where we found co-localization of nestin and SMA in 
vessels (Fig 2A-C) while only SMA staining was observed in smooth muscle layer 
around the airways (Fig 2A). 
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Fig. 2: Characterization of nestin expressing cells in pulmonary vasculature (From 
Claudia Berndt, dissertation). A-C: Immunofluorescence staining of lung sections from 
nestin-GFP transgenic mice with smooth muscle cells’ marker α-SMA. Nestin+ smooth 
muscle cells are visible in vessels (yellow-green) and nestin- negative smooth muscle 
cells are present around a bronchiole (b, red) (A). Higher magnification of 
colocalization of nestin-GFP and α-SMA in the wall of an artery (a) confirming nestin 
in vascular smooth muscle cells (B-C). D: Immunofluorescence staining of lung 
sections from nestin-GFP transgenic mice with endothelial cells’ marker CD31 showing 
nestin-GFP signal is absent in endothelial cells (e, endothelial cells; m, smooth muscle 
cell). 
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1.10 Aim of the study 
The present study was performed to investigate the role of nestin expressing vascular 
smooth muscle cells as stem cell like progenitor cells in lungs. Since nestin expressing 
vascular progenitor cells are identified in various organs including our study revealing 
progenitors of Leydig cells (Davidoff et al., 2004) and knowing that nestin expressing 
cells in lungs are vascular smooth muscle cells, we aimed; 
 To investigate a potential role of nestin expressing vascular smooth muscle cells 
in postnatal development of lung 
 To investigate a potential role of nestin expressing vascular smooth muscle cells 
in adult lungs under pathological conditions. 
In order to achieve the aims, lung samples from newborn mice and three different 
models of pulmonary hypertension (hypoxic mouse model, MCT and Su5416/hypoxia 
rat model) as well as human samples from patients of pulmonary hypertension and 
pulmonary fibrosis were used and a series of experiments were performed which are as 
follows; 
 Evaluation of nestin expression in correlation to vascular smooth muscle cell 
proliferation in postnatal development 
 Analysis of nestin expression in correlation to vascular smooth muscle cell 
proliferation in hypoxic mouse model of pulmonary hypertension 
 Analysis of nestin expression in monocrotaline and Su5416/hypoxia treated rat 
lung samples 
 Analysis of nestin expression in human lung samples from patients of 
pulmonary hypertension and pulmonary fibrosis 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Equipment 
Agarose gel electrophoresis apparatus PeqLab, Erlangen, Germany 
Cryostat, CM1900 Leica, Wetzlar, Germany 
Fluorescence microscope, Axioskop 2 plus Zeiss, Munich, Germany 
Gel documentation system  Phase, Lübeck, Germany 
High temperature Incubator Heraeus, Hanau, Germany 
iCycler IQ™ Realtime PCR detection system Bio-Rad, Munich, Germany 
MasterCycler Gradient Eppendorf, Hamburg, Germany 
Microscope Axiostar plus Zeiss, Munich, Germany 
Microtome, RM2255 Leica, Wetzlar, Germany 
PALM Laser Microdissection System Zeiss, Munich, Germany 
Polyacrylamide gel electrophoresis Hoefer, San Fransisco, USA 
apparatus (SE600) 
Power supply  Hoefer, San Fransisco, USA 
Safety Cabinet Heraeus, Hanau, Germany 
Safety Cabinet Köttermann, Uetze, Germany 
Elisa Reader Dynatech, Denkendorf, Germany 
Spectrophotometer, Biophotometer  Eppendorf, Hamburg, Germany 
Ultra centrifuge (Sorvall ultra pro 80) Sorvall, Hertfordshire, UK 
2.1.2 Kits 
Amersham™ ECL WB detection system GE healthcare, Freiburg, Germany 
Bio-Rad protein assay Bio-Rad, Munich, Germany 
Envision G|2 double staining kit DAKO, Hamburg, Germany 
GeneAmp® RNA PCR kit Applied Biosystems, 
 Darmstadt, Germany 
Horseradish peroxidase labeled polymer DAKO, Hamburg, Germany 
iScript™ cDNA synthesis kit Bio-Rad, Munich, Germany 
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Platinum® SYBR® green Invitrogen, Karlsruhe, Germany 
qPCR SuperMix-UGD 
RNeasy Micro kit  Qiagen, Hilden, Germany 
RNeasy Mini kit  Qiagen, Hilden, Germany 
2.1.3 Consumables 
Eppendorf tubes (1.5 ml/2 ml)  Eppendorf, Hamburg, Germany 
Filter tips Eppendorf, Hamburg, Germany 
PCR tubes (0.2 ml) Applied Biosystems 
 Darmstadt, Germany 
Pipettors 10, 20, 100, 200, 1000 µl Eppendorf, Hamburg, Germany 
Serological pipette: 5, 10, 25, 50 ml BD Falcon, Heidelberg, Germany 
X-ray films Fuji, Tokyo, Japan 
2.1.4 Reagents 
1-chloro-2,2,2-trifluoroethly difluoromethyl Abbott, Wiesbaden, Germany 
ether (Isoflurane) 
4',6-diamidino-2-phenylindole (DAPI)  Sigma-Aldrich, Steinheim, Germany 
Acetic Acid  Merck, Darmstadt, Germany 
Acetone  Roth, Karlsruhe, Germany 
Acrylamide solution, Rotiphorese Gel 30  Roth, Karlsruhe, Germany 
Agarose  PeqLab, Erlangen, Germany 
Amersham™ Hybond™- nitrocellulose GE healthcare, Freiburg, Germany 
membranes 
Ammonium persulfate (APS)  Roth, Karlsruhe, Germany 
AmpliTaq DNA polymerase  Applied Biosystems,  
 Darmstadt, Germany 
Aniline blue Merck, Darmstadt, Germany 
Azocarmine Chroma, Stutgart, Germany 
Bovine serum albumin (BSA)  Sigma-Aldrich, Steinheim, Germany 
Bromophenol blue  Sigma-Aldrich, Steinheim, Germany 
Calcium chloride (CaCl2•2H20)  Merck, Darmstadt, Germany 
3,3'-Diaminobenzidine (DAB) Merck, Darmstadt, Germany 
Di-Sodium hydrogen phosphate Roth, Karlsruhe, Germany 
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Dithiothreitol (DTT)  Invitrogen, Karlsruhe, Germany 
DNA low range marker (100 bp)  Fermentas, Maryland, USA 
DNase-1 Applied Biosystems,  
 Darmstadt, Germany 
Eosin Sigma-Aldrich, Steinheim, Germany 
Ethanol  Riedel de haen, Seelze, Germany 
Ethidium bromide solution  Roth, Karlsruhe, Germany 
Ethylendinitrilo-N, N, N´, N´, -tetra-acetic Roth, Karlsruhe, Germany 
acid disodium salt (EDTA) 
Glucose oxidase Sigma-Aldrich, Steinheim, Germany 
Glycerol  Roth, Karlsruhe, Germany 
Glycine  Roth, Karlsruhe, Germany 
Hepes  Sigma-Aldrich, Steinheim, Germany 
Hydrochloric acid (HCl)  Merck, Darmstadt, Germany 
Hydrogen peroxide (H2O2) Roth, Karlsruhe, Germany 
Isopropanol  Sigma-Aldrich, Steinheim, Germany 
Magnesium chloride (MgCl2•6H2O)  Merck, Darmstadt, Germany 
Mayer’s Hemalum solution Merck, Darmstadt, Germany 
Methanol  Fluka, Buchs, Switzerland 
Milk powder Roth, Karlsruhe, Germany 
Mul-V RT Applied Biosystems,  
 Darmstadt, Germany 
TEMED  AppliChem, Darmstadt, Germany 
Nickle sulfate Merck, Darmstadt, Germany 
Normal goat serum Sigma-Aldrich, Steinheim, Germany 
Orange G Sigma-Aldrich, Steinheim, Germany 
Paraformaldehyde  Roth, Karlsruhe, Germany 
Phosphotungstic acid Riedel de haen, Seelze, Germany 
Picric acid Fluka, Buchs, Switzerland 
Ponceau S solution Sigma-Aldrich, Steinheim, Germany 
Potassium chloride (KCl)  Merck, Darmstadt, Germany 
Random hexamers  Boehringer, Mannheim, Germany 
SigmaMarker™ (Molecular weight marker) Sigma-Aldrich, Steinheim, Germany 
Sodium chloride (NaCl)  Roth, Karlsruhe, Germany 
Sodium dodecyl sulphate (SDS) Roth, Karlsruhe, Germany 
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Sodium hydroxide (NaOH)  Merck, Darmstadt, Germany 
Sodium azide (NaN3) Sigma-Aldrich, Steinheim, Germany 
Thimerosal Sigma-Aldrich, Steinheim, Germany 
Tissue Tek O.C.T compound  Sakura, Zoeterwoude, Netherlands 
Tris  Roth, Karlsruhe, Germany 
Tri-Sodium citrate dihydrate Merck, Darmstadt, Germany 
Triton X-100 Sigma-Aldrich, Steinheim, Germany 
Tween 20  Sigma-Aldrich, Steinheim, Germany 
Western blocking reagent Roche, Mannheim, Germany 
Xylene Roth, Karlsruhe, Germany 
β-mercaptoethanol  Sigma-Aldrich, Steinheim, Germany 
2.1.5 Primary antibodies 
Anti-nestin Mouse monoclonal Chemicon, Schwalbach, Germany 
Anti-nestin Mouse monoclonal BD Transduction,Heidelberg, Germany 
Anti-nestin Mouse monoclonal Santa Cruz, Germany 
Anti-PDGFR-β Rabbit polyclonal Upstate, Virginia, USA 
Anti-p-PDGFR- β Rabbit polyclonal Santa Cruz, Heidelberg, Germany 
Anti-Calponin-1 Rabbit monoclonal Epitomics, Hamburg, Germany 
Anti-α-SMA Mouse monoclonal Serotec, Oxford, UK 
Anti-PCNA Mouse monoclonal Chemicon, Schwalbach, Germany 
Anti-Ki67 Rabbit polyclonal Novocartra, Newcastle, UK 
Anti-vinculin Mouse monoclonal Sigma-Aldrich, Steinheim, Germany 
Anti-β-Actin Mouse monoclonal Sigma-Aldrich, Steinheim, Germany 
2.1.6 Secondary antibodies 
Goat-anti-mouse IgG Pierce, Bonn, Germany 
Goat-anti-rabbit IgG Pierce, Bonn, Germany 
Cy3-goat-anti-mouse IgG Jackson immunoresearch, Hamburg, Germany 
Cy3-goat-anti-rabbit IgG Jackson immunoresearch, Hamburg, Germany 
Alexa-goat-anti-mouse IgG Roche, Mannheim, Germany 
Alexa-goat-anti-rabbit IgG Roche, Mannheim, Germany 
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2.2 Animals and tissues 
C57BL/6 mice were purchased from Charles River Laboratories (Sulzfeld, Germany). 
The animals had access to food and water ad libitum. The experiments were performed 
according to the guidelines for the use of laboratory animals using study protocols 
approved from local authorities (Federal Authorities for Animal Research of the 
Regierungspräsidium Giessen, Hessen, Germany). 
2.2.1 Postnatal development 
For postnatal studies, female pregnant C57BL/6 mice were purchased from Charles 
River Laboratories (Sulzfeld, Germany). After the mice gave birth to pups, the 
newborns were sacrificed at different time points after birth and tissues were frozen in 
liquid nitrogen or fixed with Bouin’s fixative and 4% PFA respectively for further 
analysis.  
2.2.2 Hypoxic mouse model 
For hypoxic experiments, male C57BL/6 mice (8 weeks) were purchased from Charles 
River Laboratories (Sulzfeld, Germany). Hypoxic pulmonary vascular remodeling was 
induced by exposure of mice to chronic hypoxia in ventilated chambers as described 
before (Weissmann et al., 2005). Animals were kept under hypoxic conditions (10% 
inspired O2 fraction) in a normobaric chamber for different time periods starting from 1 
day to 3 weeks. Constant level of hypoxia was maintained with the help of an 
autoregulatory control unit (model 4010, O2 controller, Labotec, Göttingen, Germany) 
supplying either nitrogen or oxygen to the chambers. Excessive humidity in the system 
was prevented by condensation in a cooling system. CO2 from the chambers was 
continuously removed by using soda lime. Hypoxic chambers were opened once a day 
for cleaning as well as to supply food and water. The chamber temperature was 
maintained at 22 - 24°C. Control animals were placed in similar condition in a normoxic 
chamber with normal oxygen environment (21% inspired O2 fraction) (Weissmann al., 
2005). Animals were sacrificed after normoxic/hypoxic treatment and tissues were 
frozen in liquid nitrogen or fixed with Bouin’s fixative and 4% PFA respectively for 
further analysis. 
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2.2.3 MCT rat samples 
Rat lungs from monocrotaline (MCT) treated animals (3 weeks, 4 weeks and 5 weeks 
after MCT) as well as control samples were obtained from the laboratory of Prof. 
Norbert Weissmann (Department of Internal Medicine, Medical Clinic II, Giessen, 
Germany). 
2.2.4 Su5416/hypoxia treated rat samples 
Rat lungs injected with Sugen 5416 (VEGF-2 receptor antagonist) followed by hypoxic 
treatment for 5 weeks and control samples were obtained from the laboratory of Prof. 
Ralph Schermuly (Department of Internal Medicine, Medical Clinic II, Giessen, 
Germany). 
2.2.5 Human lung samples 
Human samples from patients suffering from pulmonary hypertension, pulmonary 
fibrosis and from donor lungs as control were obtained from the laboratory of Prof. 
Ralph Schermuly (Department of Internal Medicine, Medical Clinic II, Giessen, 
Germany). 
2.3 Methods 
2.3.1 Western Blot 
2.3.1.1 Protein isolation 
Western blot analysis was performed as described before (Müller et al., 2004). In detail, 
frozen lung samples were crushed with the help of a hammer and then ground to powder 
in liquid nitrogen with the help of a mortar and pestle. Powdered tissue was suspended 
in ice cold homogenizing buffer (10ml/g of tissue) and homogenized in Potter-Elvehjem 
homogenizer. The homogenate was centrifuged at 3000 x g for 8 minutes at 4°C. The 
pellet was discarded while the supernatant contained the total isolated proteins. 
To separate cytosolic and membrane associated proteins, total proteins were further 
centrifuged at 100,000 x g for 30 minutes at 4°C. The supernatant that contained 
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cytosolic proteins was picked up by pipetting while the pellet containing membrane 
associated proteins was resuspended in 50mM Tris buffer (pH 7.5). 
Homogenization buffer components Final concentration 
Tris (pH 7.5) 50 mM 
EDTA 1 mM 
Dithiothreitol (DTT) 1 mM 
Phenylmethanesulfonyl fluoride (PMSF) 0.1 mM 
 
2.3.1.2 Estimation of protein concentration 
The quantity of protein was measured by Bio-Rad Protein Assay (Bio-Rad, Munich, 
Germany) which is based on the method of Bradford. The method involves 
incorporation of Coomassie® Brilliant Blue G-250 dye to proteins. The absorbance 
maximum of acidic solution of the dye shifts from 465 nm to 595 nm when it binds to 
the protein. Protein concentration was detected at 595 nm by microplate reader. Series 
of bovine serum albumin (BSA) (Sigma, fraction V) was used as standard solution in 
range of 3 – 18 µg/µl to measure the exact concentration of proteins in the sample. 
2.3.1.3 SDS polyacrylamide gel electrophoresis 
Protein samples of same concentration were mixed with 3x SDS gel loading buffer at a 
ratio of 2:1 (v/v) and denatured at 100°C for 2 minutes. Protein samples (60 µg for 
nestin in postnatal samples, 120 µg for nestin in hypoxic samples, 40 µg for PDGFR-β 
and p-PDGFR-β) or protein molecular weight marker (Sigma, USA) were loaded in the 
wells of 7% gel. The gel was run in SE 600 vertical electrophoresis system (Hoefer 
Scientific Instruments, MA, USA) at 13W for one hour until the samples crossed the 
stacking gel and then at 17W for about 3 hours for separation. 
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Gel running buffer components Final concentration 
Tris 25 mM 
Glycine 192 mM 
Sodium dodecyl sulfate (SDS) 0.1% (w/v) 
 
 
 
 
 
 
 
Resolving gel (7%) components Volume 
Resolving gel buffer (pH 8.8) 7.5 ml 
Acrylamide solution (30%) 7.0 ml 
Ammonium per sulphate (APS) 10% 0.25 ml 
TEMED 0.05 ml 
Distilled H2O 14.75 ml 
Total volume 30 ml 
3X gel loading buffer components Final concentration 
Tris 375 mM 
Dithiothreitol (DTT) 200 mM 
Sodium dodecyl sulfate (SDS) 15% (w/v) 
Glycerin 20% (v/v) 
Bromophenol blue 0.6 mg/dl 
Resolving gel buffer components Final concentration 
Tris 375 mM 
Sodium dodecyl sulfate (SDS) 0.1% (w/v) 
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2.3.1.4 Immunoblotting 
After separation on SDS-PAGE under reducing conditions, proteins were transferred to 
Amersham™ Hybond™-ECL nitrocellulose membranes (GE healthcare, Freiburg, 
Germany) at 30 volts for 12 – 14 hours at 4°C. To estimate the efficiency of protein 
transfer after blotting, the membranes were incubated with Ponceau-S (Sigma, Munich, 
Germany) for 10 minutes at room temperature with constant shaking. The membranes 
were washed with distilled water and scanned. After incubating with blocking solution 
(Roche, Mannheim, Germany) for 2 hours at room temperature, the immunoblots were 
probed with primary antibody [anti-nestin (Chemicon, 1:1000, for rat tissues), anti-
nestin (BD Transduction, 1:1000, for mouse tissues), anti- PDGFR-β (Upstate, 1:500) 
and anti-p-PDGFR-β (Santa Cruz, 1:250)] diluted in antibody incubation buffer (90% 
TBS-T, 10% blocking buffer and 0.005% Thimerosal). After washing with TBS-T, blots 
were incubated with respective horseradish peroxidase conjugated secondary antibody 
Stacking gel buffer components Final concentration 
Tris 500 mM 
Sodium dodecyl sulfate (SDS) 0.1% (w/v) 
Stacking gel (7%) components Volume 
Stacking gel buffer (pH 6.8) 5.0 ml 
Acrylamide solution (30%) 2.7 ml 
Ammonium per sulphate (APS) 10% 0.1 ml 
TEMED 0.025 ml 
Distilled H2O 2.175 ml 
Total volume 10 ml 
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(goat-anti-mouse IgG, 1:2000 or goat-anti-rabbit IgG, 1:2000 from Pierce). After 
washing, the blots were treated with Amersham™ enhanced chemiluminescence (ECL) 
reagents (GE healthcare, Freiburg, Germany) and the chemiluminescence signal was 
captured on X-ray film (Fuji, Tokyo, Japan). 
Blotting buffer components Final concentration 
Tris 100 mM 
Glycine 193 mM 
 
TBS-T components Final concentration 
Tris 20 mM 
Sodium Chloride (NaCl) 137 mM 
Tween 20 0.05% (v/v) 
 
2.3.1.5 Densitometry 
Densitometric quantification of Western blots was performed using Image-J software 
(NIH, Bethesda, Maryland, USA). Expression of proteins was quantified using band 
intensity values which were normalized to β-Actin or vinculin. Statistical analysis was 
performed using Graphpad prism version 4 (Graphpad software, San Diego, California, 
USA). 
2.3.2 Immunohistochemistry 
For immunohistochemistry, 8 µm thick lung sections from Bouin fixed paraffin 
embedded tissues were used. After deparaffinization in xylene and rehydration in series 
of decreasing ethanol concentration, sections were subjected to microwave treatment in 
sodium citrate buffer (pH 6.0) for antigen retrieval or directly preceded to serum 
blocking step. After blocking of unspecific binding sites in 2% normal goat/rabbit 
serum (Sigma-Aldrich, Steinheim, Germany) for 1 hour at room temperature, sections 
were incubated overnight at 4°C with primary antibody [anti-nestin(BD Transduction, 
1:50, for mouse tissues), anti nestin (Chemicon, 1:50, for rat tissues), anti nestin (Santa 
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Cruz, 1:50, for human tissues), anti-PCNA (Chemicon, 1:25), anti-Ki67 (Novocastra, 
1:1000), anti-Calponin-1 (Epitomics, 1:500) and anti-α-SMA (Serotec, 1:500)] diluted 
in PBS with 0.2% BSA and 0.1% sodium azide. After washing with PBS, horseradish 
peroxidase labeled polymer (DAKO, Hamburg, Germany) was applied to the sections 
for 1 hour at room temperature. Peroxidase activity was detected using DAB by nickel-
glucose oxidase approach (Davidoff et al., 1995).  
For double staining of paraffin embedded lung sections, after initial processing 
(deparaffinization, antigen retrieval, blocking etc.), Envision G|2 double staining kit 
(Dako, Hamburg, Germany) was used for double staining according to manufacturer’s 
instructions. 
For immunofluorescence, 10 µm thick frozen sections from tissues fixed with 4% PFA 
or unfixed lungs were used. The sections from unfixed tissue were fixed with ice cold 
acetone at -20°C for 10 minutes followed by air drying step of 5 minutes and again 
fixation with acetone for 10 minutes. After cutting cryosections from prefixed tissue or 
fixation with acetone, antigen retrieval and blocking of unspecific binding sites, sections 
were incubated overnight at 4°C with primary antibody [anti-nestin (BD Transduction, 
1:50), anti-Ki67 (Novocastra, 1:1000), anti- PDGFR-β (Upstate, 1:100) and anti-p-
PDGFR-β (Santa Cruz, 1: 50)]. After washing with PBS, slides were subjected to Cy3 
(Jackson immunoresearch, Hamburg, Germany) or Alexa Fluor (Roche, Mannheim, 
Germany) conjugated secondary antibody and 4´,6-diamidino-2-phenyl-indole (DAPI, 
1µg/ml) for 1 hour at room temperature. Sections without primary antibody treatment 
served as controls. 
2.3.3 Azan staining 
Heidenhain’s AZAN staining method was performed on 8 µm thick lung sections from 
bouin fixed paraffin embedded tissues. After deparaffinization in xylene and 
rehydration in series of decreasing ethanol concentration, slides were incubated with 
Azocarmine solution at 56°C for 15 minutes. After washing with distilled water, slides 
were placed in 0.1% aniline alcohol until the cytoplasm and connective tissue became 
pale pink and nuclei were well defined. After rinsing the slides in 1% acetic alcohol and 
washing with distilled water, the slides were incubated in 5% phosphotungstic acid for 2 
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hours. After washing the slides were treated with aniline blue/orange-G solution for 
about 1 hour.  
The slides were dehydrated in ethanol and cleared by three changes in xylene and 
coverslips were mounted using Eukitt® mounting medium (Fluka, Buchs, Switzerland). 
Images were obtained by conventional light and fluorescence microscopy using 
Axioskop 2 plus microscope and Axiovision software (Zeiss, Munich, Germany). 
2.3.4 Laser assisted microdissection 
Laser assisted microdissection of lung vessels was done with the help of PALM Laser 
Microdissection System with auto-catapult and Robocut Software (Zeiss, Munich, 
Germany). 10 µm lung cryosections were transferred to PALM membrane coated slides 
(Zeiss, Munich, Germany). Sections were fixed with ethanol and stained with 
hematoxylin. After 10 minutes of air drying, pulmonary vessels were microdissected 
and catapulted into oil-coated caps of sterile 0.5 ml tubes. Minimum 50 – 70 vessels 
corresponding to minimum 300,000µm2 of required samples were collected per tube. 
2.3.4.1 RNA isolation and cDNA synthesis 
Total RNA from microdissected samples was extracted using RNeasy mini or micro kit 
(Qiagen, Hilden, Germany). Microdissected vessels were dissolved in lysis buffer with 
β-mercepto-ethanol. RNA was isolated using DNase on column digestion. Eluted RNA 
concentration was measured was used to synthesize 1st strand cDNA. 
Genomic DNA contaminations were removed by DNase I [Invitrogen, Karlsruhe, 
Germany (1 U/reaction)] digestion for 15 min at 37°C. Synthesis of cDNA was 
performed according to the manufacturer’s instructions using iScript™ cDNA synthesis 
kit (Bio-Rad, Munich, Germany) or alternatively with the help of GeneAmp® RNA 
PCR kit (Applied Biosystems, Darmstadt, Germany). 
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Recipe for cDNA synthesis with iScript™ cDNA synthesis kit 
Reagents Amount per reaction 
5X iScript reaction mix 4 µl 
iScript reverse transcriptase 1 µl 
RNA 1 µg 
H2O Up to 20 µl 
Conditions for the reaction were 5 min at 25°C, 30 min at 42°C, and 5 min at 85°C. 
Recipe for cDNA synthesis with GeneAmp® RNA PCR kit 
Reagents Amount per reaction 
10X PCR buffer 2 µl 
2mM MgCl2 4 µl 
10mM dNTPs 1 µl 
Random Hexamers 1 µl 
RNase inhibitor 0.5 µl 
Mul-V RT 1 µl 
H2O 0.5 µl 
Reaction conditions for cDNA synthesis were 10 min at 20°C, 75min at 43°C, and 5 
min at 99°C. 
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2.3.4.2 RT PCR 
The intron-spanning primer pairs for PCR were designed with the Primer3 program 
(http://frodo.wi.mit.edu/primer3/) and synthesized from Eurofins (MWG synthesis 
GmbH, Ebersberg, Germany). Primers were cross checked by blasting with the whole 
genome to ensure specificity.  
Target Sequence Length 
Nestin 
For 5´- AGGCTGAGAACTCTCGCTTG - 3´ 
152 bp 
Rev 5´- TGAGAAGGATGTTGGGCTGA - 3´ 
SMA 
For 5´- CTGACAGAGGCACCACTGAA - 3´ 
160 bp 
Rev 5´- CATCTCCAGAGTCCAGCACA - 3´ 
β-Actin For 5´- GTGGGAATGGGTCAGAAGG - 3´ 300 bp 
Rev 5´- GGCATACAGGGACAGCACA - 3´ 
The cDNA was amplified with target specific primer pairs according to manufacturer’s 
instructions. 
Recipe for PCR mix 
Reagents Amount per reaction 
10x PCR buffer 2.5 µl 
2mM MgCl2 2.5 µl 
10mM dNTPs 0.5 µl 
Forward primer 0.25 µl 
Reverse primer 0.25 µl 
ATG polymerase 0.2 µl 
cDNA 1 µl 
H2O Up to 20 µl 
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Reaction conditions for PCR included initial denaturation of 15 min at 94°C followed 
by 40 cycles of 30 sec at 94°C, 20 sec at 60°C, 20 sec at 72°C and the final extension of 
10 min at 72°C.  
2.3.4.3 Agarose gel electrophoresis 
PCR products were separated by electrophoresis on 2% agarose gels prepared in Tris-
acetate-EDTA (TAE) buffer. 0.5 mg/ml ethidium bromide was added to gel to visualize 
DNA bands under UV light afterwards. Amplified product along with DNA ladder was 
loaded on to the gel and electrophoresis was done at a constant voltage of 130V for 30 
min. PCR products were visualized under UV light and documented using a gel 
documentation system (Phase, Lübeck, Germany). 
Positive controls for primers were run by using reversely transcribed total RNA from 
tissues abundantly expressing the respective target sequences (brain for nestin and lung 
for SMA). Negative controls were performed by omitting the reverse transcriptase 
during cDNA synthesis. 
TAE buffer components Final concentration 
Tris 40 mM 
Glacial acetic acid 20 mM 
EDTA 1 mM 
2.3.4.4 Real-time PCR 
Quantitative real time PCR was performed on iCycler iQ™ real time PCR system (Bio-
Rad, Munich, Germany) using Platinum® SYBR® green qPCR SuperMix-UGD 
(Invitrogen, Karlsruhe, Germany) according to manufacturer’s instructions.  
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Recipe for Real time PCR mix 
Reagents Amount per reaction 
SYBR green master mix 10 µl 
Forward primer 0.25 µl 
Reverse primer 0.25 µl 
H2O Up to 20 µl 
 
Reaction conditions for real time PCR 
Step Time Temperature Cycle 
Initial denaturation 8.5 min 95°C 1 
Denaturation 20 sec 95°C  
Primer annealing 20 sec 60°C 40 
Extension 20 sec 72°C  
Denaturation 1 min 95°C 1 
Dissociation curve Indefinite 55-95°C 1 
Final hold Indefinite 4°C 1 
 
Each reaction was run in triplicate and repeated three times independently. Negative 
controls were run omitting the cDNA template. In the end, PCR product was separated 
on 2% agarose gel as quality control to confirm product size and avoid false positive 
bands. 
Real time PCR data was analyzed using iQ™ 5 Optical system software (Bio-Rad, 
Munich, Germany). Using the software, a dissociation curve was generated for each 
gene to ensure single product amplification and the threshold cycle (Ct values) for each 
gene was determined. The samples showing false positive bands or melting curve with 
more than one peak were not included in data analysis. The comparative 2-ΔΔCt method 
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was used to analysis mRNA fold changes between normoxic and hypoxic lung samples, 
which was calculated as;  
Ratio = 2-(ΔCt normoxic-ΔCt hypoxic) 
where Ct is the threshold cycle and ΔCt (Ct target-Ct reference) is the Ct value 
normalized to the reference/housekeeping gene β-Actin obtained for the same cDNA 
sample for both normoxic and hypoxic samples. The calculated 2-ΔΔCt value was 
transformed into a percentage using the normoxic as 100% to show the difference in 
expression of mRNA. 
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3 Results 
As shown before in a recent study by our group, nestin expression is present in lung 
vasculature. Nestin was found predominantly in arteries while veins and capillaries also 
showed nestin expression. Nestin+ cells in vasculature were characterized as vascular 
smooth muscle cells and pericytes (Fig. 2, Dissertation, Claudia Berndt). 
In the present study, it was intended to investigate whether nestin+ progenitor cells are 
involved in development and remodeling. For this purpose we investigated, in detail, 
postnatal development and pulmonary hypertension. The reason of choosing postnatal 
development and pulmonary hypertension as models for our study was that both 
processes are associated with fundamental changes in vasculature of lungs and 
according to our hypothesis, that nestin+ progenitor cells might be involved in these 
vascular changes. 
3.1 Postnatal Development 
During postnatal development, along with alveolarization, vasculature of lung also 
undergoes remodeling (Burri, 2006; Ni et al, 2010). Lung samples from postnatal mice 
were used to evaluate nestin expression and proliferation in vasculature of lungs. 
3.1.1 Comparison of nestin expression and VSMC proliferation between 
postnatal d1 and adult 
Using nestin GFP mice our colleague Claudia Berndt showed that significantly higher 
amounts of nestin are expressed in lungs of postnatal d1 mice as compared to adults 
(Fig. 3A, 3B). Nestin was found only in cells of vasculature while the smooth muscle 
cells around the bronchioli were negative for nestin (Fig. 2C). Anti nestin antibodies 
were used to confirm whether the GFP signal really represents the nestin staining and a 
co-localization of nestin and GFP staining was observed in vasculature of lungs.
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Fig. 3: Comparison of nestin-GFP expression in lungs from post natal d1 and adult 
mouse. A-B: High amount of Nestin-GFP staining at postnatal d1 (A) compared to adult 
lung sample (B). C-E: Colocalization of nestin and nestin-GFP (arrows). C: GFP 
signal. D: Anti-nestin immunofluorescence. E: Merged photo from vessel with anti-
nestin and GFP staining. 
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The observation of significantly higher nestin expression in postnatal d1 lungs as 
compared to adults was confirmed by Western blot analysis (Fig. 4A). 240 kDa protein 
bands in this Western blot analysis clearly correspond to nestin-GFP data. Brain 
samples from postnatal day 1 were routinely used as positive control for nestin in 
Western blots. Vinculin was used as loading control. 
Next it was of interest whether nestin expression at day 1 correlates with higher 
proliferation rates of vascular smooth muscle cells, shown to express nestin (Fig. 2B-D). 
For this purpose, vascular smooth muscle cell proliferation was compared between 
lungs from postnatal d1 and adults using proliferation marker PCNA. Lungs from 
postnatal d1 showed high vascular smooth muscle cell proliferation (Fig. 4B) while 
there was no proliferation of vascular smooth muscle cells in adult samples (Fig. 4C). 
Epithelial cells of bronchioli which proliferate regularly, served as internal positive 
controls (arrowheads, Fig. 4C). Mouse testes that showed positive PCNA staining in 
nuclei of proliferating germ cells were used as further positive controls and to optimize 
immunohistochemistry protocol (Fig. 4D-E). 
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Fig. 4: Comparison of nestin expression and smooth muscle cell proliferation in mouse 
postnatal development; day 1 (d1) vs. adult (ad). A: Western blot analysis showed high 
amount of nestin in d1 lung samples. In adults, nestin was barely detectable. (60 µg 
protein was used for each sample) Brain sample from postnatal d1 mouse was used as 
positive control for nestin and vinculin was used as loading control. B-E: PCNA 
immunohistochemistry to reveal cell proliferation. B-C: Comparison of vascular 
smooth muscle cell proliferation between d1 and adult using PCNA antibodies. VSMCs 
in vessels (*) of d1 lungs showed marked proliferation as compared to adult (arrows). 
Proliferating epithelium serves as internal positive control (arrowheads). D-E: PCNA 
immunohistochemistry in mouse testis sections, used as further positive control, showed 
positive staining in spermatogonia. 
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3.1.2 Nestin expression and VSMC proliferation at different time points of 
postnatal development 
Since postnatal changes in structure of mouse lung are not restricted to time 
immediately after birth (Burri, 2006), a series of further time points was used to 
investigate nestin expression and cell proliferation  
Using Western blot analysis it was found that during postnatal development, lungs 
showed maximum nestin expression from postnatal d3 till d10 that reduced gradually 
during the course of development (Fig. 5A). Interestingly, nestin expression during the 
period between d3 and d10 was even higher than on d1 (Figs. 3 and 4) which was found 
to be much higher than in adults. 
In agreement, proliferation of vascular smooth muscle cells also increased during early 
postnatal development with maximum proliferation between postnatal d3 and d10 (Fig. 
5B-5E) that reduces gradually as the development proceeds (Fig. 5F) with adult samples 
showing no VSMC proliferation (Fig. 5G).  
Expression pattern of nestin showing peak of nestin at d3-d10 is quite similar to 
proliferation of vascular smooth muscle cells with maximum proliferation in d3-d10 
samples which strongly suggests that there is a definite correlation between nestin 
expression and proliferation of vascular smooth muscle cells in lungs. 
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Fig. 5: Analysis of nestin expression and vascular smooth muscle proliferation in 
postnatal development. A: Western blot showing increased nestin expression between 
d3 and d10 (60 µg protein per lane). β-Actin was used as loading control. B-G: PCNA 
immunohistochemistry. Proliferating smooth muscle cells are clearly visible (arrows) in 
lung samples from postnatal d1, d3, d7, d10 and d15 (B-F). Lung section from adult 
mouse showing no proliferation of vascular smooth muscle cells (G). Proliferating 
epithelial cells serve as internal positive control (arrowheads). Arteries are marked by 
asterisks (*). 
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3.2 Mouse model of chronic hypoxia 
Chronic hypoxia results in pulmonary hypertension and is characterized by vascular 
remodeling (Pak et al 2007) that is known to be visible after three weeks of hypoxic 
exposure. To investigate nestin expression and role of nestin+ cells in the process of 
vascular remodeling, mice were exposed to hypoxic conditions for different time 
periods up to 3w and series of experiments were performed including measurement of 
nestin mRNA level in micro-dissected arteries, analysis of nestin protein expression and 
proliferation of vascular smooth muscle cells in hypoxic lung samples. 
3.2.1 Nestin mRNA levels in microdissected arteries from hypoxic lung 
samples 
Since nestin was found to be localized predominantly in pulmonary arteries (Fig. 2), 
nestin expression was investigated in laser assisted microdissected arteries located in 
close proximity to bronchioli (Fig. 6A, 6B). Using RT-PCR, nestin was detected in 
pulmonary arteries (Fig. 6C).  
3.2.2 Nestin protein expression in hypoxic lung samples 
Western blot analysis of hypoxic samples taken after different time periods showed that 
exposure to hypoxia resulted in a characteristic pattern of nestin expression. Nestin 
expression in lungs increased significantly after three days of hypoxic exposure and 
remained up-regulated until one week under hypoxia and eventually came to normoxic 
level after three weeks of hypoxic treatment (Fig. 7). 
It was an interesting observation that realtime PCR analysis from laser assisted 
microdissected arteries (data not shown) provides evidence for a peak of nestin mRNA 
expression immediately before day 3 after hypoxia and decrease to normoxic levels 
immediately thereafter. 
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Fig. 6: RT PCR analysis for nestin expression in laser-assisted microdissected arteries 
from hypoxic lung samples. A-B: Photos showing arteries before and after 
microdissection. C: Agarose gel electrophoresis showing nestin expression in 
microdissected vessels. M= DNA ladder, “+” represents the normal PCR reaction, “-” 
represents the negative control with the same ingredients excluding reverse transcriptase 
during reverse transcription step and “0” indicates the water negative control. 
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Fig. 7: Western blot analysis of nestin expression in cytosolic protein extracts from 
hypoxic lung samples (120 µg protein per sample). A: Nestin Western blot showing 
increase in nestin expression between 3d and 1w of hypoxic treatment that decreases 
and comes to normoxic level after 3w. Vinculin was used as loading control. B: 
Densitometric quantification of Western blots showing peak of nestin between 3d and 
1w of hypoxic exposure. Bars show mean scores (+/- SD) from 3 assessments. a,b P < 
0.05; a indicates that there was a significant difference when NOX values were 
compared with 1d, 3d, 4d, and 1w values each;  b indicates that there was a significant 
difference when 3w values were compared with the 1d, 3d, 4d and 1w values each. 
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3.2.3 Proliferation of vascular smooth muscle cells in hypoxic lung samples 
Immunohistochemistry of hypoxic samples with the proliferation markers PCNA 
revealed that there was no proliferation of vascular smooth muscle cells until one day 
after hypoxia (Fig. 8A-B). At three days after hypoxic treatment a significant number of 
proliferating vascular smooth muscle cells could be observed (Fig. 8C). Maximum 
number of proliferating vascular smooth muscle cells was observed after four days of 
hypoxic treatment (Fig. 8D). Amount of proliferating vascular smooth muscle cells 
decreased after 1 week under hypoxia (Fig. 8E) and eventually in 3 weeks hypoxic 
samples there were no proliferating vascular smooth muscle cells (Fig. 8F). 
The same pattern of proliferating cells was visible when analyzing expression of another 
proliferation marker (Ki67) at the same time points under hypoxia. Again, there was no 
proliferation of vascular smooth muscle cells in normoxic and 1 day hypoxic samples 
(Fig. 9A-B) with significant increase of vascular smooth muscle cell proliferation at 3 
days (Fig. 9C) and maximum proliferation at 4 days under hypoxia (Fig. 9D) followed 
by decrease in number of proliferating vascular smooth muscle cells after 1 week under 
hypoxia (Fig. 9E) and finally no proliferation of vascular smooth muscle cells after 3 
weeks of hypoxic exposure (Fig. 9 F). 
Specific pattern of nestin expression in hypoxic samples showing increase in nestin 
between 3 days and 1 week again correlates to increased proliferation of vascular 
smooth muscle cells during the same time period under hypoxia. This data is consistent 
with data of nestin expression and vascular smooth muscle cell proliferation in postnatal 
development suggesting again a strong correlation between nestin expression and 
proliferation. 
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Fig. 8: Immunohistochemical analysis of vascular smooth muscle proliferation using 
proliferation marker PCNA. A-B: Vascular smooth muscle cells showing no 
proliferation in normoxic lung sample as well as in hypoxic lung sample 1d after 
hypoxic exposure. C-D: Vascular smooth muscle cells showing maximum proliferation 
in lungs isolated 3d and 4d after hypoxic treatment. E: After 1w of hypoxic exposure, 
lung samples show significantly reduced proliferation of smooth muscle cells. F: 3w 
hypoxic samples show no smooth muscle cell proliferation. Arteries are indicated by 
asterisks (*). 
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Fig. 9: Immunohistochemical analysis of vascular smooth muscle proliferation using 
proliferation marker Ki67. A-B: Vascular smooth muscle cells showing no proliferation 
in normoxic lung sample as well as in hypoxic lung sample 1d after hypoxic exposure. 
C-D: Vascular smooth muscle cells showing maximum proliferation in lungs isolated 
3d and 4d after hypoxic treatment. E: After 1w of hypoxic exposure, lung samples show 
significantly reduced proliferation of smooth muscle cells. F: 3w hypoxic samples show 
no smooth muscle cell proliferation. Arteries are indicated by asterisks (*). 
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3.2.4 VSMCs represent the proliferating cell types in hypoxic vascular 
remodeling 
Hypoxic lung samples were analyzed using double staining with smooth muscle marker 
α-SMA and proliferation marker PCNA (Fig. 10) to prove whether the proliferating 
cells are really vascular smooth muscle cells. In normoxic and 3 weeks hypoxic samples 
staining of smooth muscle cells is visible only while in 3 days and 4 days hypoxic 
samples, along with staining of α-smooth muscle actin in smooth muscle cells (red 
color), PCNA marked nuclei (stained in brown color) are clearly visible (Fig. 10A-B). 
This data from dual color immunohistochemistry confirms that in hypoxic lung 
samples, the proliferating cells in pulmonary vasculature are the vascular smooth 
muscle cells. It is worth mentioning here that we did not find any proliferation of 
endothelial cells (or adventitial cells) in hypoxic mouse samples. 
 
A B
α-SMA + PCNA: 4dα-SMA + PCNA: 3d 50m 50m  
Fig. 10: Dual color immunohistochemical staining of hypoxic lung samples. Red color 
represents α-SMA highlighting the smooth muscle cells in vessels as well as around the 
airways (arrowheads) while PCNA+ nuclei in brown color show proliferating cells. In 
arteries of 3d (A) and 4d (B) hypoxic samples, along with α-SMA, PCNA+ nuclei are 
also visible representing α-SMA+ proliferating vascular smooth muscle cells (arrows). 
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3.2.5 Nestin+ subpopulation of VSMCs shows proliferation 
Multicolor immunofluorescence technique was also applied on hypoxic lung samples 
using antibodies against nestin and proliferation marker Ki67 as well as DAPI. In 
normoxic and 3 weeks hypoxic samples, only DAPI+ nuclei could be observed while 
nestin staining was barely detectable (Fig. 11A, D). In samples where increased nestin 
expression and proliferation of vascular smooth muscle cells was found, nestin 
localization could be observed in cytoplasm of a subpopulation of vascular smooth 
muscle cells and these nestin+ cells also showed proliferation which is visible by 
localization of Ki67 in nuclei (marked by DAPI) of nestin+ cells in 3 days and 4 days 
hypoxic samples (Fig. 11B-C). 
This experiment showing proliferation of nestin+ VSMCs proved the correlation 
between nestin expression and proliferation suggesting the involvement of a sub-
population of nestin+ vascular smooth muscle cells in postnatal development and 
vascular remodeling. 
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Fig. 11: Multicolor immunofluorescent staining of hypoxic lung samples. Green color 
identifies nestin immunoreactivity while Ki67+ nuclei in red color represent 
proliferating cells. Nuclei are stained with DAPI. A: In normoxic sample, only DAPI+ 
nuclei are visible without additional red staining (Ki67). B, C: In 3d and 4d hypoxic 
samples, nestin+ vascular smooth muscle cells are also  positive for the proliferation 
marker Ki67 (arrows). D: In 3w hypoxic sample, there are DAPI+ but no Ki67+ nuclei.  
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3.2.6 Different sub-types of vascular smooth muscle cells in media 
Since we were able to demonstrate that only a sub-population of vascular smooth 
muscle cells expressed nestin and showed proliferation, we wanted to investigate 
whether different sub-types of smooth muscle cells exist in vessel wall. Therefore, we 
used calponin to mark smooth muscle cells of contractile phenotype (Owens, 1995; 
Sobue et al., 1999). After 4 days of hypoxic exposure, where we found maximum 
proliferation of vascular smooth muscle cells, it appears that two distinct sub-
populations of vascular smooth muscle cells could be distinguished, one contractile 
phenotype showing strong calponin staining (arrows) and another with down-regulated 
calponin signal (arrowheads) indicating change of contractile phenotype to synthetic 
phenotype in a subpopulation of vascular smooth muscle cells. In opposite, all smooth 
muscle cells around the airways showed strong calponin staining suggesting a 
contractile phenotype only (Fig. 12A-B). Different to 4 days, in normoxic and 3 weeks 
hypoxic samples where no nestin expression and proliferation of smooth muscle cells 
was observed, there was strong calponin staining in vessels as well as around the 
airways (Fig. 12C-D).  
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Fig. 12: Calponin immunohistochemistry of hypoxic lung samples to differentiate 
between a more contractile and a more synthetic phenotype of smooth muscle cells. A-
B: After 4d of hypoxia, contractile SMCs around the bronchiole (b) showing strong 
calponin staining (arrows) while in blood vessels two populations of SMCs are clearly 
visible where cells with stronger (arrows) and low (arrowheads) calponin staining could 
be discriminated. C-D: Under normoxia and 3w hypoxia, strong calponin staining is 
visible in SMC of both airways and vessels (a, artery; b, bronchiole). 
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3.2.7 PDGFR-β expression during the course of vascular remodeling 
PDGF-B/PDGFR-β signaling is known to be involved in vascular remodeling mediating 
the proliferation and migration of vascular smooth muscle cells (Schermuly et al, 2005). 
Western blot analysis was performed to investigate expression pattern of PDGFR-β and 
phosphorylated/activated PDGFR-β. There is slight but gradual increase in expression 
of PDGFR-β during the progression of pulmonary hypertension (Fig. 13A). On the 
other hand Western blot analysis and densitometric quantification clearly showed that 
its active form p-PDGFR-β showed a peak between 4 days and 1 week of hypoxic 
treatment with a tendency of decrease of p-PDGFR-β thereafter (Fig. 13B-C). This 
pattern of PDGFR-β phosphorylation could be correlated to nestin expression and 
proliferation of vascular smooth muscle cells.  
Summarizing the results from hypoxic mouse model, it could be concluded that there 
was significant increase in nestin mRNA prior to day 3 after hypoxia which is followed 
by up-regulation of nestin protein and increase in proliferation of vascular smooth 
muscle cells at 3 days after hypoxia and in the end peak of the p-PDGFR-β from 4 days 
till 1 week after hypoxia. Interestingly, nestin expression and proliferation of vascular 
smooth muscle cells were down-regulated and came to normoxic levels after 3 weeks of 
hypoxic treatment when pulmonary hypertension is known to be established and is 
clearly visible clinically and histologically. 
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Fig. 13: Western blot analysis of PDGFR-β and p-PDGFR-β. A: Blot showing gradual 
increase of PDGFR-β (190 kDa) expression along with the progression of pulmonary 
hypertension (40 µg membrane protein per sample). B: Immunoblot showing peak of p-
PDGFR-β (190 kDa) expression at 4d – 1w after hypoxia (40 µg membrane protein per 
lane). Vinculin served as loading control. C: Densitometric quantification of p-PDGFR-
β expression. Bars show mean scores (+/- SD) from 3 assessments. Quantified values of 
each time point under hypoxia were compared with values of normoxic controls (*P < 
0.05). 
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3.3 Nestin in MCT rat samples 
To investigate whether nestin+ vascular smooth muscle cells are also involved in 
monocrotaline induced vascular remodeling, nestin immunohistochemistry was 
performed on MCT treated rat samples. Nestin was found in vascular smooth muscle 
cells in rat lung samples after 3 weeks and 4 weeks of MCT treatment (Fig. 14A-B) 
while control samples without MCT treatment were negative for nestin 
immunoreactivity (Fig. 14D). Double staining of MCT treated rat lung sections with 
nestin and α-smooth muscle actin confirmed that nestin is expressed by a sub-
population of vascular smooth muscle cells (Fig. 14C).  
Nestin expression in A. pulmonalis (pulmonary artery) and aorta of MCT treated rats 
was compared using Western blot analysis. In A. pulmonalis of MCT treated samples 
there is significant increase in nestin expression as compared to respective control, 
while there is no difference in nestin expression in aorta from control and MCT treated 
rats (Fig. 14E). This Western blot analysis suggests that MCT induced increase in nestin 
expression and hence vascular changes are associated with only pulmonary circulation 
with no or minimal effect on systemic circulation. 
Different to hypoxic mouse model, in large arteries of MCT treated rat samples, in 
addition to vascular smooth muscle cells, nestin staining was also observed in a specific 
zone at the border of media and adventitia (Fig 15A-C) which was previously described 
as “vasculogenic zone” harboring stem/progenitor cells (see Klein et al, 2010). Double 
staining with nestin and α-smooth muscle actin clearly shows that in addition to nestin 
in vascular smooth muscle cells, nestin+ cells are also present outside the medial layer 
(Fig. 15 A-B). This data suggests the presence of nestin+ stem/progenitor cells in a 
certain area of vascular adventitia. Azan staining was also used to clearly differentiate 
between different layers of vascular wall and to determine the exact location of nestin+ 
cells shown by nestin immunohistochemistry (Fig. 15D).  
 
Results 
- - 67 - - 
 
 
Fig. 14: Nestin expression in monocrotaline treated rat samples. A-B: Nestin 
immunostaining in vascular smooth muscle cells of small vessels (ca. 100 µm diameter) 
after 3w and 4w of monocrotaline treatment. C: Double staining of MCT treated lung 
sample showing nestin+ cells (brown) are smooth muscle cells (red). D: Rat lung sample 
without MCT treatment showing no nestin immunostaining. E: Immunoblot showing 
comparison between nestin expression in MCT treated aorta and A. pulmonalis.  
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Fig. 15: Nestin staining in large vessels (> 200 µm diameter) of monocrotaline treated 
rat samples. A-C: Nestin immunohistochemistry (C) and double staining (A-B) showing 
additional nestin expression in adventitial cells (arrows) close to media (previously 
described as “vasculogenic zone”). D: Azan staining of lung samples showing the three 
vascular layers intima, media and adventitia. 
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3.4 Nestin in rat samples treated with Sugen 5416 and hypoxia  
Nestin expression was also investigated in rats treated with VEGF-2 receptor antagonist 
Su5416 and hypoxia. In this model, similar to hypoxic mouse and MCT rat models, 
nestin expression was also found in vascular smooth muscle cells of arteries 5 weeks 
after treatment with Su5416 and hypoxia (Fig. 16A-C). Double staining and co-
localization of nestin and α-smooth muscle actin confirmed the presence of nestin in 
vascular smooth muscle cells (Fig. 16C). Control samples from animals that were not 
treated with Su5416 and hypoxia, showed no nestin expression (Fig. 16D). In the 
Su5416/hypoxia model, however, there are additional characteristic features that do not 
appear in hypoxic or MCT models, e.g. formation of complex lesions (Abe et al., 2010). 
In very small arteries (ca. 30-50 µm diameter), that are supposed to be non-muscular 
arteries in normal conditions and get muscularized during vascular remodeling, 
additional nestin immunoreactivity could be observed outside the media (Fig. 17A-D). 
These nestin+ perivascular cells may contribute to muscularization of previously non-
muscular arteries. Double staining with nestin and α-smooth muscle actin confirmed 
that nestin is also present outside the media (Fig. 17C-D).  
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Fig. 16: Nestin expression in rats treated with Sugen5416 and hypoxia. A-B: Nestin 
expression in vascular smooth muscle cells (arrows). C: Colocalization of α-smooth 
muscle actin (red) and nestin (brown) confirming nestin in vascular smooth muscle 
cells. D: Control rat samples without Su5416 and hypoxic treatment showing no nestin 
in the vasculature. 
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Fig. 17: Nestin expression in very small arteries (ca. 30-50 µm diameter) of rats treated 
with Sugen5416 and hypoxia. A-B: In addition to VSMCs (arrowheads), nestin 
expression was found outside the media in these very small vessels. C-D: Double 
staining of such vessels with α-smooth muscle actin (red) and nestin (brown) 
confirming that nestin is present within (arrowhead) and outside the media (arrows).  
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In small arteries (ca. 70-80µm diameter), different phenotypes of thickened intima could 
be observed and interestingly, in all such arteries nestin was expressed in vascular 
smooth muscle cells (Fig. 18A-H). While analyzing different phenotypes of arteries 
with thickened layer of intima it can be assumed that remodeling of vessels is initiated 
by accumulation of extracellular matrix in the vessel wall resulting in two layers of 
vascular smooth muscle cells, an inner thin layer and an outer media layer (Fig. 18A, 
C). The accumulation of extracellular material seems to be followed by infiltration or 
migration of nestin+ vascular smooth muscle cells into the extracellular matrix since 
single nestin+ (also α-SMA+) vascular smooth muscle cells were visible in the 
extracellular matrix (Fig. 18E-H). In addition, reduction of lumen was also visible. Both 
processes might contribute to formation of neointima, a characteristic feature of this 
animal model.  
In large vessels (>200 µm diameter), similar to the MCT treated rat samples, nestin 
immunostaining was found in adventitial cells close to media (Fig. 19A-D). Double 
staining with nestin and α-smooth muscle actin again confirmed the presence of nestin+ 
cells outside the media at the border of media and adventitia (Fig. 19C-D). 
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Fig. 18: Different patterns of nestin expression in VSMCs of small arteries (ca. 70-80 
µm diameter) suggesting involvement of nestin+ VSMCs in the development of 
neointima in rats treated with Sugen5416 and hypoxia. A-H: α-SMA (A, C, E, G) and 
nestin (B, D, F, H) expression in serial sections of small arteries indicating 
colocalization of nestin and α-SMA. A-D: Accumulation of extracellular material 
(asterisks) in media resulting in two layers of VSMCs. E-H: Vessels suggesting inward 
infiltration of nestin+ VSMCs (arrows), resulting in the reduction of lumen.
 
Results 
- - 74 - - 
 
 
A B
α-SMA
Nestin: 5w Su5416 + hypoxia
Nestin: 5w Su5416 + hypoxia
C D
Nestin: 5w Su5416 + hypoxia
α-SMA
Nestin: 5w Su5416 + hypoxia
100m
50m 100m
50m
 
 
Fig. 19: Nestin expression in large arteries (>200 µm diameter) of rats treated with 
Sugen5416 and hypoxia. A, B: In larger vessels, nestin immunoreactivity in adventitial 
cells at the junction of media and adventitia (arrows). C-D: Double staining showing 
nestin (brown, arrows) outside the media. 
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As compared to large arteries of hypoxia/Su5416 rat model which show nestin 
expression in the small, so-called “vasculogenic zone” between media and adventitia 
(Fig. 19A-D) which is barely visible in lower magnification (Fig. 20A-B), the large 
veins show nestin expression in the whole media which is clearly visible even at lower 
magnification (Fig. 20A-D). Interestingly, these nestin+ cells in veins represent 
cardiomyocytes that can be easily identified in azan stained histological sections (Fig. 
20E-H). The presence of cardiomyocytes in large pulmonary veins of rodents has been 
described before (Josef et. al. 2008). In hypoxia/Su5416 model, as shown before during 
development, in hypoxic mouse model (Fig. 11) and in MCT rat model (Fig. 14), 
smooth muscle layer around bronchi and bronchioli do not show any staining for nestin. 
Different to hypoxic mouse model, the data from rat models suggests that nestin marks 
the progenitor cells at different locations within the vessel. 
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Fig. 20: Nestin expression in large veins (>500 µm diameter) of rats treated with 
Sugen5416 and hypoxia. A-D: Nestin immunostaining in cardiomyocytes present in 
these large pulmonary veins (a, artery; b, bronchiole; v, vein). E-H: Azan staining 
showing cardiomyocytes in wall of pulmonary veins. G-H: Higher magnification 
showing striated cardiomyocytes (asterisks) in vein.  
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3.5 Nestin in human samples from patients suffering from pulmonary 
hypertension 
Using immunohistochemistry, nestin expression was investigated in lung samples from 
patients suffering from pulmonary hypertension. As compared to healthy control lungs, 
high nestin expression was observed in pulmonary vessels (Fig. 21-22). Nestin 
expression was observed in vascular smooth muscle cells of very small (ca. 10-20 µm 
diameter) and small (ca. 50-100 µm diameter) vessels (Fig. 21A-E). Double staining 
with nestin and α-smooth muscle actin confirmed the vascular smooth muscle cell 
localization of nestin in small vessels (Fig. 21E). In large arteries (>200 µm diameter), 
similar to the rat models, in addition to vascular smooth muscle cells there was also 
nestin expression in adventitial cells in so-called “vasculogenic zone” at the border of 
media and adventitia (Fig. 21G-H). 
Pulmonary hypertension in humans is characterized by specific vascular lesions e.g. 
concentric lesions and plexiform lesions. Nestin was also found in both concentric (Fig. 
22A) and plexiform (Fig. 22B) types of vascular lesions as well as in vessels 
undergoing recanalization at the site of thrombosis (Fig. 22C) suggesting potential role 
of nestin+ progenitor cells in development of these lesions. 
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Fig. 21: Nestin immunohistochemistry in very small (ca. 10-20 µm diameter, A-B), small 
(ca. 50-100 µm diameter, C-F) and large  (>200 µm diameter, G-H) arteries of human lung 
samples from patients suffering from pulmonary hypertension (A-E, G-H) and from 
healthy control lungs (F). A-B: Nestin expression in VSMCs (arrows) of very small lung 
vessels. C-E: Nestin expression in VSMCs (arrows) of small vessels. Double staining and 
colocalization of nestin (brown) and α-SMA (red) showing nestin in VSMCs (E, arrows). 
F: Section from healthy lung samples showing no nestin immunoreactivity. G-H: Double 
staining with nestin and α-SMA showing nestin in adventitial cells of large vessels outside 
the media.  
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Fig. 22: Nestin immunohistochemistry in complex lesions of arteries in case of 
progressive remodeling of human lungs from patients suffering from pulmonary 
hypertension. A: Nestin expression in a typical concentric lesion found in pulmonary 
hypertension. B: Nestin expression observed in a plexiform lesion of pulmonary 
hypertension. C: Nestin expression found at the site of recanalization of an artery after 
thrombosis. 
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3.6 Nestin in human samples from patients suffering from pulmonary 
fibrosis 
As pulmonary fibrosis is also characterized by vascular changes (Parra et al, 2005; 
Farkas et al, 2011), nestin immunohistochemistry was also performed in lung samples 
from patients suffering from pulmonary fibrosis. Enhanced expression of nestin was 
found in vascular smooth muscle cells of large (>200 µm diameter) (Fig. 23A) and 
small (<150 µm diameter) vessels (Fig. 23C-H) as well as in some capillaries (Fig. 23D 
marked by arrowheads). In control samples from healthy persons, there was no nestin 
expression (Fig 23I-J). 
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Fig. 23: Nestin immunohistochemistry in human lung samples from patients suffering 
from pulmonary fibrosis (A-H) and from healthy control lungs (I-J). A: Nestin 
expression in VSMCs (arrows) of large arteries (>200 µm diameter). B-H: Nestin+ 
VSMCs (arrows) in small arteries (<150 µm diameter). E-F: Colocalization of nestin 
(brown) and α-SMA (red) confirming nestin in VSMCs (arrows). I-J: Sections from 
healthy lung samples showing no nestin immunoreactivity. 
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4 Discussion 
In this study it is shown that nestin expression and vascular smooth muscle cell 
proliferation increased in early postnatal development. Nestin was found in vasculature 
of lungs from different animal models (hypoxic mouse model, MCT and 
Su5416/hypoxia rat models) and human samples. In hypoxic mouse model, nestin was 
exclusively found in vascular smooth muscle cells. These nestin+ vascular smooth 
muscle cells were found to proliferate from 3 days to 1 week of hypoxic exposure and 
nestin expression and vascular smooth muscle cell proliferation reduced to normoxic 
level after 3 weeks under hypoxia. In MCT and Su5416/hypoxia treated rats and human 
samples from patients suffering from pulmonary hypertension, there was enhanced 
nestin expression in vascular smooth muscle cells as compared to controls. In rat 
models and human samples, there was additional nestin expression in certain cells of 
adventitia i.e. in the so called vasculogenic zone which is also known to harbor 
stem/progenitor cells. Nestin+ progenitor cells may play significant role in vascular 
changes both during postnatal development and progression of diseases like pulmonary 
hypertension. 
We were able to demonstrate nestin expression and localization in vasculature of lungs 
during development as well as in vascular remodeling in adults using different animal 
models and human samples. Nestin, that was initially identified as a marker of neural 
stem and progenitor cells (Lendahl et al., 1990), is expressed in various cell types in 
embryonic and adult tissues. Nestin expression is associated with stem/progenitor cell 
populations with capability to proliferate, migrate and differentiate into different cell 
types (see Wiese et al., 2004). There are only few studies showing nestin expression in 
lung. (Amoh et al., 2005; Amoh et al., 2006). 
For the first time, we were able to show nestin localization predominantly in vascular 
smooth muscle cells, both during development and vascular remodeling. In this context, 
there are only few studies that describe nestin expression in vascular smooth muscle 
cells in vivo or in vitro but no data showing nestin localization in vascular smooth 
muscle cells of lung. Nestin+ stem/progenitor cells were suggested to play a role in 
development of atherosclerosis as nestin expression was found in smooth muscle cells 
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of coronary atherosclerotic lesions (Suguta et al., 2007). Progenitor cells of testosterone 
producing Leydig cells were revealed by nestin expression in vascular smooth muscle 
cells and pericytes of testicular blood vessels (Davidoff et al., 2004). Furthermore, a 
recent study described nestin expression in medial vascular smooth muscle cells of rat 
aorta from late embryogenesis to adulthood (Oikawa et al., 2010) showing transient 
nestin expression in vascular smooth muscle cells which decreases after birth in region 
dependent manner. The in vitro studies showed that nestin expression in cultured 
vascular smooth muscle cells is induced by serum and is regulated by extracellular 
signal-regulated kinase (ERK) pathway mediated through PDGF and EGF receptors 
(Huang et al., 2008; Huang et al., 2009; Oikawa et al., 2010). 
4.1 Postnatal development 
Birth itself represents a drastic change in the environment of lung with lung liquid being 
replaced by air. Postnatal development of lung is also characterized by dramatic 
changes in lung structure.  
In this context, we found significant differences in nestin expression and vascular 
smooth muscle cell proliferation between postnatal day 1 and adult. At birth, human 
lungs are immature with conductive airways and peripheral respiratory airspaces. The 
air spaces at this stage are of classical saccular type. The walls of these air spaces are 
made of thick septa with a central layer of connective tissue sandwiched between two 
layers of capillary networks. At this stage the capillaries face the airspace from only one 
side. On the other hand, the adult setup is entirely different. The inter-alveolar wall is 
accompanied by only a single capillary network exposed to airspaces on both sides of 
alveolar wall as it meanders through the axial tissue framework (Zeltner and Burri, 
1987). The pre-acinar arteries are already present in the lungs of 20 week old fetus 
(Hislop and Reid, 1972) while intra-acinar arteries appear during later embryonic stages 
and postnatal period, side by side with the formation of alveolar duct and alveoli 
(Haworth, 1995). After birth, the size and number of these arteries increases rapidly 
during early post natal development at the same rate as number of alveoli. 
Simultaneously, the thickness of pulmonary arteries especially the media decreases by 
means of reduction in overlap of vascular smooth muscle cells without any decrease in 
 
Discussion 
- - 84 - - 
number of vascular smooth muscle cells hence reducing the mean diameter of media 
(Hislop and Reid, 1973; Allen and Haworth, 1988). 
While studying nestin expression and VSMC proliferation in a series of samples from 
postnatal development, we found highest numbers of nestin expressing vascular smooth 
muscle cells, which were able to proliferate, between day 3 and day 10 after birth 
suggesting strong correlation between nestin expression and proliferation. This data is 
in agreement with previous findings (Oikawa et al., 2010) where during postnatal 
development in rats, nestin expression was also found in vascular smooth muscle cells 
residing in media of aortic arch and abdominal aorta 6 weeks after birth. Interestingly, 
these nestin+ smooth muscle cells were found to be proliferating as marked by BrdU. 
Moreover, the vasculature of mouse trachea, which is frequently used as model to study 
airway vasculature (McDonald, 1994; Baluk et al., 2005), undergoes rapid 
reorganization and changes pattern after birth. Tracheal blood vessels regress from 
postnatal day 1 to day 3 and new vessels appear between day 3 and day 7. Our 
observation of increase in nestin expression and proliferation of vascular smooth muscle 
cells between postnatal day 3 and day 10 is consistent with increased number of 
vascular sprouts and pericytes during remodeling of tracheal vasculature (Ni et al., 
2010). Mice are born with immature lungs at saccular stage. The alveolar stage starts at 
around postnatal day 4 and alveolarization completes at around postnatal day 14 (Amy 
et al., 1977). The increased proliferation of nestin expressing VSMCs can be related to 
remodeling of existing vasculature, formation of alveoli and accompanying capillary 
network during alveolar stage after birth.  
Here it can be speculated that nestin+ vascular smooth muscle cells my also contribute 
to development of bronchial tree and formation of alveoli as a potential cellular source. 
This speculation is supported by previous findings of differentiation of nestin+ vascular 
smooth muscle cells and pericytes into Leydig cells (Davidoff et al., 2004) and 
differentiation of pericytes into skeletal muscles (Dellavalle et al., 2007). 
Our preliminary data shows an increase in polysialated NCAM in vascular smooth 
muscle cells of lungs from postnatal day 7 to day 15 that appeared after the up-
regulation of nestin indicating growth of vascular smooth muscle cells. In agreement, 
during development and maturation of neurons, PSA-NCAM is transiently expressed 
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after nestin (Seki and Arai, 1993; von Bohlen, 2007). Polysialated NCAM may 
contribute to the molecular mechanisms inducing cell proliferation and migration not 
only during development but also in the adult (Bonfanti and Theodosis, 1994; Lledo et 
al., 2006). 
 
Fig. 24: Timeline of lung postnatal development showing overview of changes in nestin 
expression (brown), vascular smooth muscle cell proliferation (blue) and PSA-NCAM 
(Green). 
4.2 Pulmonary hypertension 
Pulmonary hypertension is characterized by structural changes in pulmonary arteries 
(Durmowicz and Stenmark, 1999; Mandegar et al., 2004). We used three frequently 
used animal models (Hypoxic mouse model, MCT and Su5416/hypoxia rat models) and 
human samples from patients suffering from pulmonary hypertension and pulmonary 
fibrosis to investigate nestin expression in vascular remodeling during progression of 
pulmonary hypertension. In all animal models as well as in human samples, we were 
able to demonstrate an increase in nestin expression in vasculature of lung. 
4.2.1 Hypoxic mouse model 
In the hypoxic mouse model, we found up-regulation of nestin mRNA expression after 
2 days of hypoxic exposure while peak of nestin protein was found one day later after 3 
days of hypoxic exposure which remained up-regulated till 1 week and came to normal 
after 3 weeks of hypoxic exposure. In mice, hypoxia induced pulmonary hypertension 
d1 d4 d7 d10 d15 ad d3 
Nestin Protein 
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develops in 3 weeks which can be clearly identified histologically and clinically i.e. 
peak of nestin expression precedes pulmonary hypertension. 
Analyzing the hypoxic samples for VSMC proliferation, we found increased number of 
proliferating vascular smooth muscle cells during the same time period where we found 
increased nestin levels i.e. at 3 days and 4 days after hypoxia that decreased towards 1 
week and was absent in 3 week hypoxic samples. In previous studies, while analyzing 2 
days, 4 days, 6 days, 10 days, 16 days and 3 weeks hypoxic lungs, Paddenberg and 
colleagues described hypoxia induced proliferation of VSMCs within first week of 
hypoxic exposure (Paddenberg et al., 2007). In another study, where only 2 days, 4 
days, 6 days and 3 weeks hypoxic samples were analyzed, enhanced VSMC 
proliferation was observed in 4 days and 6 days hypoxic samples with no proliferation 
at 3 weeks after hypoxic treatment (Quinlan et al., 2000). 
It is of interest that all the vascular smooth muscle cells were not Nestin+. It was only a 
subpopulation of vascular smooth muscle cells which was Nestin+ and able to 
proliferate as marked by a labeling of Nestin and proliferation marker Ki67. This data is 
consistent with data of nestin in testicular blood vessels where only a sub-population of 
vascular smooth muscle cells was nestin+ and proliferating (Davidoff et al., 2004).  
In this context it is noteworthy that the tunica media of pulmonary arteries is composed 
of different populations of vascular smooth muscle cells (Frid et al., 1994; Yoshida and 
Owens, 2005). Depending upon the morphology and expression of molecular markers, 
these different populations of vascular smooth muscle cells can be divided into 
“contractile” and “synthetic” types. Contractile vascular smooth muscle cells can be 
characterized by typical spindle shaped nuclei and elongated cell phenotype. They 
express molecular markers like smooth muscle myosin heavy chain (SM-MHC), 
calponin and caldesmon (Owens, 1995; Sobue et al., 1999). Synthetic type vascular 
smooth muscle cells are cuboidal shaped cells which lack contractile markers and 
express non-muscular myosin heavy chain A and B (Kuro et al., 1991; Stenmark and 
Frid, 1998). We were able to differentiate between two distinct subpopulations of 
smooth muscle cells in vasculature using calponin as marker of contractile cells. One 
contractile phenotype with strong calponin immunoreactivity and the other phenotype 
with down-regulated calponin expression suggesting change of phenotype in a 
 
Discussion 
- - 87 - - 
subpopulation of vascular smooth muscle cells during enhanced proliferative activity. 
One of the most interesting features of smooth muscle cells is that they are not 
terminally differentiated in mature vascular tissue, allowing modulation of their 
phenotype under certain conditions. SMC dedifferentiation and change of phenotype is 
suggested to be an important aspect of vascular remodeling (Owens et al., 2004; Muto 
et al., 2007). Only few factors are identified that are implicated in smooth muscle cells’ 
phenotype switching and PDGF-BB (see below) is one of them (Kawai and Owens, 
2006; Muto et al., 2007). 
Interestingly, the smooth muscle cell layer of the airways, which did not express nestin, 
comprised only calponin+ smooth muscle cell population. The presence of nestin only in 
vascular smooth muscle cells but not in airway smooth muscle cells also support the 
hypothesis of occurrence of two different phenotypes of vascular smooth muscle cells. 
In agreement, nestin was only expressed in vascular smooth muscle cells with no nestin 
in peritubular contractile cells in testis (Davidoff et al., 2004).  
By demonstrating nestin expression in a subpopulation of vascular smooth muscle cells, 
we propose nestin as marker of synthetic type of vascular smooth muscle cells that are 
thought to proliferate and play important role in progression of vascular diseases like 
pulmonary hypertension (Stenmark and Frid, 1998). 
It is worth mentioning that in our hypoxic mouse model, nestin expression and cell 
proliferation could only be observed in vascular smooth muscle cells while endothelial 
cells were negative for nestin and did not show any proliferation. In agreement to our 
findings, it is described in a recent study that there is no increase in endothelial cell 
proliferation in hypoxia induced rat or mouse models of pulmonary hypertension (Yu 
and Hales, 2010). In addition, human pulmonary artery endothelial cells do not show 
any significant cell proliferation and cell cycle progression under hypoxia in vitro (Yu 
and Hales, 2010). Moreover, nestin expression is described in proliferating endothelial 
cells during tumor angiogenesis (Sugawara et al., 2002; Mokry et al., 2004) including 
lungs (Amoh et al., 2005; Amoh et al., 2006) but according to the magnification shown 
in above mentioned publications it is only speculative that nestin derived green 
fluorescent protein is really present in capillary endothelial cells. It may also be present 
in the pericytes as the pericytes and endothelial cells are covered by the same basement 
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membrane (Diaz-Flores et al., 2009) and it is extremely difficult to differentiate between 
them using normal microscopy unless you use electron microscopy or specific markers. 
Instead, nestin has been found preferentially in pericytes and vascular smooth muscle 
cells of tumor vessels (Friedrich et al., 2012). 
Several growth factors and signaling pathways are known to be involved in progression 
of pulmonary hypertension including VEGF, FGF, TGF-β, PDGF (Schermuly et al., 
2011). We were able to demonstrate a slight increase in expression of PDGFR-β during 
progression of pulmonary hypertension while the expression of phosphorylated 
(activated) PDGFR-β showed a peak between 4 days and one week after hypoxia which 
precede up-regulation of nestin expression and the onset of vascular smooth muscle cell 
proliferation under hypoxia, hence, confirming involvement of PDGF-BB/ PDGFR-β 
signaling in progression of hypoxia induced pulmonary hypertension. In support of our 
observation, under hypoxic conditions in vitro, arterial smooth muscle cells showed 
higher PDGFR-β expression and proliferation (Chanakira et al., 2012). PDGF promotes 
the proliferation and migration of vascular smooth muscle cells and PDGF-BB/PDGFR-
β signaling is known to be involved in progression of pulmonary hypertension 
(Schermuly et al., 2005; Perros et al., 2008; Li et al., 2010; Bhola et al., 2011). PDGF-
BB is reported to stimulate the proliferation of vascular smooth muscle cells during 
vascular remodeling through a HIF-1 dependent mechanism (Abedi and Zachary, 1995; 
Muto et al., 2007) PDGF inhibitors result in reversal of pulmonary vascular remodeling/ 
pulmonary hypertension (Schermuly et al., 2005).  
PDGFR-β has also been described in vascular progenitor cells of tissues other than 
pulmonary vasculature. Newly generated Leydig cells as well as their progenitors 
(vascular smooth muscle cells and pericytes) showed PDGFR-β expression (Davidoff et 
al., 2004). PDGFR-β is also used as meanwhile established marker of pericytes (Bergers 
and Song, 2005) and circulating smooth muscle progenitor cells (Sugiyama et al., 
2006). The thickening of arteries and muscularization of previously non-muscular 
arteries were suggested to be due to differentiation of precursor pericytes and 
“intermediate cells” (Meyrick and Ried, 1980) Intermediate cells were defined as 
intermediates between pericytes and smooth muscle cells. 
 
Discussion 
- - 89 - - 
There is increasing evidence that pericytes represent or are at least closely related to 
mesenchymal stem cells (Crisan et al., 2008). These cells were shown to be capable of 
renewing a variety of cell types (Crisan et al., 2008; Kovacic et al, 2009) such as Leydig 
cells (Davidoff et al., 2004), skeletal muscle cells (Dellavalle et al., 2007) osteoblasts, 
chondrocytes and adipocytes (see Crisan et al., 2008). Most recently, even the ischemic 
limbs were shown to be healed by cells exhibiting the features of vascular pericytes, 
when using multipotent progenitor cells derived from embryonic stem cells and induced 
pluripotent stem cell-derived regenerative units (Dar et al., 2012; Peault, 2012). 
Recently, we found that pericytes, in pulmonary vasculature, also express nestin 
(Berndt, 2011).  
Apart from a role in vascular smooth muscle cell proliferation and migration PDGF 
receptors are also involved in early anti-apoptotic responses. PDGF-B/ PDGFR-β 
signaling in isolated neurons, is involved in cell survival and protection from pro-
apoptotic stimuli for up to 48h under hypoxia (Zhang et al., 2003). In brainstem of adult 
rats, hypoxia induced phosphorylation of PDGFR-β was associated with activation of 
anti-apoptotic mechanisms through Akt/BAD signaling pathway (Simakajornboon et 
al., 2010). Our unpublished results also show results in the same direction as we 
observed increase in PDGFR-β phosphorylation as early as 6 hours – 15 hours under 
hypoxia. 
VEGF is up-regulated in rats with hypoxic treatment but down-regulated in MCT 
treated rats (Partovian et al., 1998). Hypoxia, in combination with VEGF receptor 
inhibition using VEGF receptor antagonist Su5416, results in severe pulmonary 
hypertension (Taraseviciene-Stewart et al., 2001), a model for experimental pulmonary 
hypertension that we also used in this study (see 1.2.3).  
Thioredoxin (Trx) is a ubiquitously expressed protein that is important for maintaining 
the oxidative balance within the cell. There are two isoforms of theoredoxin, Trx-1 and 
Trx-2 (Collet, 2010). Trx-1 levels in hypoxic lung samples also showed characteristic 
pattern similar to the expression patterns of nestin expression and vascular smooth 
muscle cells proliferation (Data not shown) suggesting that redox signaling may also be 
involved in hypoxia induced vascular remodeling. Trx-1 protein expression was 
recently described to be necessary for hypoxia induced proliferation of pulmonary 
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artery smooth muscle cells (Nelin, 2011). Trx-1 is known to enhance neovascularization 
in chronic myocardial infarction (Adluri et al., 2011). Increased thioredoxin levels at the 
time of increased nestin expression and vascular smooth muscle cell proliferation could 
be associated with vascular remodeling. It is thinkable that under conditions of reduced 
oxygen concentration, Trx-1 and nestin might be up-regulated via the same hypoxia 
induced transcriptional control. 
Summarizing the data from hypoxic mouse model, the timeline of events taking place in 
this model are as follows. Nestin mRNA shows peak after 2 days under hypoxia. Nestin 
protein up-regulation occurs at 3 days after hypoxic exposure followed by increase in 
vascular smooth muscle cell proliferation and in the end phosphorylation of PDGFR-β 
after 4 days – 1 week of hypoxic treatment. Expression of all the proteins and 
proliferation of vascular smooth muscle cells comes to normoxic level before week 3 of 
hypoxic exposure when the complete histological characteristic and the distinct clinical 
symptoms are visible. 
 
 
Fig. 25: Timeline of experimental pulmonary hypertension (mice under hypoxia) 
showing overview of changes in nestin mRNA (red) nestin protein (brown), PDGFR-β 
(orange) and p-PDGFR-β (green) expression and vascular smooth muscle cell 
proliferation (Blue). 
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4.2.2 MCT rat model 
Monocrotaline treated rats are widely used as model for experimental pulmonary 
hypertension (Stenmark et al., 2009; Gomez-Arroyo et al., 2012). Increased nestin 
expression was also observed in vascular smooth muscle cells of monocrotaline treated 
rat lung samples. In addition to vascular smooth muscle cells, nestin+ cells were also 
observed in the adventitia of pulmonary vessels. Vascular adventitia has been 
designated as a niche of potential progenitor cells that contribute to pathogenesis of 
pulmonary hypertension by proliferating and migrating to intima or media (Hinz et al., 
2007). In recent years, it has been shown that resident stem and progenitor cells of large 
and medium sized arteries are predominantly localized in a specific zone at the border 
of media and adventitia. This zone is named as “vasculogenic zone” (Ergun et al., 
2011). Our observation of nestin in vascular adventitia may represent nestin in 
stem/progenitor cells in this so-called vasculogenic zone.  
In MCT rat model, we found nestin in vascular tree in a time dependent manner i.e. in 
smaller vessels after 3 weeks and 4 weeks of MCT treatment and in large vessels after 5 
weeks of MCT treatment. It is known that vascular remodeling during pathogenesis of 
pulmonary hypertension starts in smaller vessels and spreads through the vascular tree 
into large vessels. Muscularization of small previously non-muscular arteries starts as 
early as 2 days under hypoxia (Quinlan et al., 2000) 
While comparing nestin expression in A. pulmonalis and aorta of MCT treated and 
control rats, we found that, nestin up-regulation was found only in A. pulmonalis while 
there was no difference in nestin expression in aorta of MCT treated and untreated rats 
that suggest that in MCT induced pulmonary hypertension, the increase of nestin in 
vascular smooth muscle cells during proliferation may be specific for the pulmonary 
circulation with no effect in systemic vasculature. This particular effect may be due to 
the reason that MCT is activated in the liver and pulmonary vasculature represents the 
first major vascular bed distal to liver (Marsboom and Janssens, 2004) and the activated 
metabolic product of MCT, “MCT pyrrole” is quickly degraded in aqueous solutions 
like plasma (Wilson et al., 1992). 
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It is known that along with vascular remodeling, the application of MCT also activates 
other processes e.g. peri-vascular inflammation and platelet activation (Wilson et al., 
1992). These additional MCT effects might coincide with an increase of degradation of 
certain cytoplasmic proteins such as GSK-3 (Müller, personal communication) and 
nestin. It is thinkable that in this model, the variety of nestin immunoreactive signals 
(nestin degradation products) in Western blot is also responsible for immunostaining of 
further cell types other than vascular smooth muscle cells e.g. cells of adventitia. 
4.2.3 Su5416/Hypoxia model 
Hypoxia in combination with VEGF receptor antagonist, Sugen 5416, which results in 
formation of characteristic lesions of pulmonary hypertension, is also used as animal 
model to study vascular remodeling (Taraseviciene-Stewart et al., 2001; Sakao et al., 
2005; Abe et al., 2010). In this model, after 5 weeks of Su5416 injection and hypoxic 
treatment we were able to demonstrate nestin expression in both arteries and veins. 
Similar to the monocrotaline rat model, nestin was observed in vascular smooth muscle 
cells of the media of arteries. This animal model resembles the traditional 
monocrotaline model of pulmonary hypertension with prominent perivascular 
inflammatory infiltrates (Stenmark et al., 2009). In the Su5416/hypoxia model, 
however, there are additional characteristics in nestin localization depending on the size 
of vessels and the degree of remodeling. 
One of the characteristic features of hypoxia induced pulmonary hypertension is 
muscularization of previously nonmuscular arteries (Jones et al., 2008; Rabinovitch, 
2008; Stenmark et al., 2009). In very small arteries (ca. 30-50 µm diameter) of the 
Su5416/hypoxia model, which could derive from such non muscular arteries, nestin was 
observed in a perivascular pattern outside the media. These nestin+ cells might represent 
special perivascular cells that are suggested to increase during development of 
pulmonary hypertension and contribute to neo-muscularization of small arteries (Sluiter 
et al., 2012).  
In certain small arteries (ca. 70-80µm diameter), where nestin was found in vascular 
smooth muscle cells, it can be suggested that extracellular matrix accumulates in vessel 
wall resulting in two layers of vascular smooth muscle cells, one inner thin layer close 
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to lumen and another outer layer of media smooth muscle cells. This observation is 
consistent with previous findings in fibrosis of lamina propria in testes, regularly 
consisting of multiple layers, where accumulation of extracellular material also resulted 
in two layers of contractile cells (Volkmann et al., 2011).  
The accumulation of extracellular material seems to be the first step in remodeling of 
these vessels followed by infiltration or migration of nestin+ vascular smooth muscle 
cells into the extracellular matrix that might contribute to formation of neointima. In 
agreement, it is reported that smooth muscle cells present in neointimal lesions are 
locally derived from the vessel wall and not from bone marrow cells (Bentzon et al., 
2007; Hagensen et al., 2010). De-differentiated smooth muscle cells that are found to be 
highly proliferative, migrate toward the lumen of the vessel (from the tunica media into 
the tunica intima), thus resulting in the development of a neointimal lesion (Owens et 
al., 2004; Muto et al., 2007). The proposed hypothesis of extracellular material 
accumulation followed by inward migration of vascular smooth muscle cells is only 
based upon observation of different phenotypes of arteries. Detailed analysis, however, 
of formation of such lesions at different time points of Su5416/hypoxia treatment is still 
to be performed. 
Another interesting finding in this model was the nestin expression in large pulmonary 
veins. The media of these large veins was mainly comprised of nestin+ cardiomyocytes. 
Cardiomyocytes were described in pulmonary veins of mice, rats and humans (Mueller-
Hoecker et al., 2008). Nestin has also been reported in cardiomyocytes (Scobioala et al., 
2008; Mokry et al., 2008). Nestin+ cardiomyocyte-like cells with striated pattern were 
also shown to reside in adult heart that contributes in healing the infarcted heart (El-
Helou et al., 2005). In Su5416/hypoxia model, we were able to analyze nestin 
expression only 5 weeks after Su5416 injection and hypoxic treatment and the detailed 
expression pattern of nestin after different time periods of Su5416 and hypoxic 
treatment still remains to be investigated. 
Nestin expression in rats is found in multiple cell types as compared to mice that 
showed nestin predominantly in vascular smooth muscle cells. To support our 
observation, it is described that under hypoxia, mice develop less pulmonary arterial 
thickening than rats and the vascular remodeling is less pronounced in mice as 
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compared to rats (Hoshikawa et al., 2001; Hoshikawa et al., 2002). In addition, it has 
been demonstrated that there is heterogeneous remodeling of pulmonary arteries in 
hypoxic and MCT rat models in different segments of pulmonary arterial tree (van 
Suylen et al., 1998). Higher degree of vascular remodeling in rats and heterogeneous 
remodeling in different segments of pulmonary arterial tree might explain the presence 
of additional nestin+ progenitor cells in so-called “vasculogenic zone”. In large vessels, 
vessel wall resident progenitor cells were described in a distinct zone at the border 
between media and adventitia (Zengin et al., 2006; Klein et al., 2010; Ergun et al., 
2011) and Zengin and colleagues termed this zone as “vasculogenic zone”. Further 
explaining the presence of progenitor cells in vasculogenic zone at the border between 
media and adventitia, one can think of the German term of “letzte wiese”. “Letzte 
wiese” is the area in heart or brain which is deprived of oxygen because it is present at 
the border zone of blood supply from different arteries. The oxygen deprived areas 
develop infarcts known as borderzone infarct or watershed infarct (Mangla et al., 2011). 
In large vessels of rats and humans, where we found nestin+ cells in “vasculogenic 
zone”, one can assume that this zone being present at the border between media and the 
adventitia might also be deprived of oxygen. Stronger nestin expression in progenitor 
cells might be induced due to hypoxic conditions in this region. 
4.2.4 Human samples 
Significantly increased nestin expression was observed in different cell types in human 
samples from patients suffering from pulmonary hypertension. Pulmonary hypertension 
in humans is characterized by specific lesions (Wagenvoort and Wagenvoort, 1970, 
Pietra et al., 2004) and most prominent are plexiform and concentric lesions. While 
comparing human pulmonary hypertension with animal models, these characteristic 
lesions are not developed in most of the animal models which is quite a draw back in 
investigating the pathogenesis of these structures in human pulmonary hypertension. It 
is of interest that in addition to nestin in vascular smooth muscle cells and in cells of 
“vasculogenic zone” between media and adventitia of large vessels, nestin was found in 
all types of lesions in currently investigated human samples. We assume nestin is 
expressed in smooth muscle cells and other proliferating progenitor cells present in 
these lesions. Concentric lesion is composed of proliferating myofibroblasts and medial 
smooth muscle cells resulting in narrowing of lumen (Wagenvoort and Wagenvoort, 
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1970). Regarding the cell components of plexiform lesion, there were different views in 
the past. The cell types in plexiform lesions were described as smooth muscle cells, 
endothelial cells or myofibroblasts (Naeye and Vennart, 1960; Wagenvoort and 
Wagenvoort, 1977; Smith and Heath, 1979) but later on, studies using molecular 
markers have addressed this concern and endothelial cells were found to be the 
predominant cell type along with smooth muscle cells and inflammatory cells (Tuder et 
al., 1994; Cool et al., 1999). The presence of nestin in plexiform lesion may represent 
proliferating endothelial progenitor cells involved in pathogenesis of these lesions that 
comes either from circulating source or the resident pool in “vasculogenic zone” as 
described previously (Zengin et al., 2006). Moreover, a recent study demonstrated that 
there was no evidence of enhanced endothelial cell proliferation in pulmonary 
vasculature of rat and mice under hypoxia (Yu and Hales, 2011). 
Pulmonary fibrosis is known to be associated with vascular changes as patients 
suffering from pulmonary fibrosis also develop severe pulmonary hypertension (Pitsiou 
et al., 2011). In this context we found very high nestin expression in vascular smooth 
muscle cells of arteries in human samples from patients suffering from pulmonary 
fibrosis. The vascular changes start with destruction of pulmonary capillaries by fibrotic 
tissues (Renzoni et al., 2003) followed by neovascularization in fibrotic tissue and 
increase in vascularization in nonfibrotic or least fibrotic tissue (Renzoni et al., 2003; 
Ebina et al., 2004). Our observation of nestin in fibrotic samples may support the 
hypothesis that increased vascular density in least fibrotic tissues has a role in 
regeneration of alveolar septa that is damaged by fibrotic process (Ebina et al., 2004). 
On the other hand, nestin+ cells in the vessels of fibrotic samples may contribute to 
fibrotic process serving as the source of myofibroblasts. In agreement to this 
assumption, vascular smooth muscle cells and pericytes were suggested to be involved 
in vessel repair and are suggested to contribute to fibrosis in scleroderma (Rajkumar et 
al., 2005; Hinz et al., 2007). 
In case of human samples, we only got samples from patients that were at the end stage 
of disease and were considered for lung transplant. It is not possible to get human 
samples from different stages of disease, and due to this discrepancy, it is not possible 
to investigate in detail, the fate of nestin+ cells during the progression of disease and we 
have to rely on animal models. 
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4.3 Nestin as marker of proliferating stem/progenitor cells 
After investigating different animal models and human samples and describing nestin 
expression in lung vasculature, we postulate that certain resident progenitor cells could 
be identified in vasculature using nestin as a marker of proliferating resident progenitor 
cells. Nestin expression has been described in a variety of cell types in different organs 
during development as well as in adults (Wiese et al., 2004; Krupkova et al., 2010). 
Davidoff et al. demonstrated nestin as marker of proliferating vascular smooth muscle 
cells and pericytes that represented progenitors of Leydig cell (Davidoff et al., 2004). 
Hair follicle sheath cells marked by nestin (Li et al., 2003) were described as source of 
dermal blood vessels (Amoh et al., 2004) which play important role in survival and 
wound healing after skin transplant (Aki et al., 2010). Nestin expression was widely 
observed in newly formed blood vessels at the site of tumor angiogenesis (Chen et al., 
2010; Krupkova et al., 2010; Ishiwata et al., 2011; Friedrich et al., 2012) and is 
suggested to be a useful marker to identify neovasculature in the cancerous tissue 
(Teranishi et al., 2007). Nestin+ vascular wall cells were also suggested to contribute to 
tumorigenesis (Friedrich et al., 2012). Nestin expression in combination with 
proliferation markers Ki67 or PCNA in different tumors has been designated as marker 
for angiogenesis (Gravdal et al., 2009; Yamahatsu et al., 2012). 
4.4 Nestin as prognostic or diagnostic marker 
Another important finding in our hypoxic mouse model was up-regulation of nestin 
quite early (after 3 days of hypoxic exposure) compared to histological and clinical 
features that appear after 3 weeks of hypoxic treatment. This observation suggests that 
nestin expression might be used as a prognostic or diagnostic marker to deal with 
certain diseases like pulmonary hypertension. In support of this idea, nestin expression 
has been suggested as diagnostic and prognostic marker of malignancy in certain tumors 
(Ehrmann et al., 2005; Svachova et al., 2011; Arai et al., 2012). Nestin expression was 
described as prognostic indicator of poor survival probability for patients suffering from 
resected non-small cell lung cancer that might be used to select patients who should 
receive adjuvant chemotherapy (Ryuge et al., 2011).  
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Furthermore, due to its early appearance in the progression of disease, nestin could be a 
potential novel molecular target to inhibit vascular remodeling in vascular diseases like 
pulmonary hypertension. In agreement, nestin is suggested to be a potential therapeutic 
target to inhibit tumor angiogenesis (Yamahatsu et al., 2012). 
4.5 Nestin+ cells in potential therapeutic and healing strategies 
After establishing the fact that nestin+ cells are involved in tissue repair in adults, in 
recent years, many studies have evaluated the plasticity of nestin+ cells isolated form 
different organs and these nestin+ cells, when grown in appropriate conditions, give rise 
to neurons, astrocytes, oligodendrocytes, blood vessels and cardiomyocytes (see 
Calderone, 2012). It has been suggested that nestin+ cells could be isolated to be used in 
cell based therapies (Birbrair et al., 2011). The possibility of nestin+ cells in healing the 
infarcted heart has been reviewed in a recent publication (Calderone, 2012). 
4.6 Function of nestin 
Nestin expression has been described in a variety of cell types in different organs during 
development as well as in adults (Wiese et al., 2004; Krupkova et al., 2010) but its exact 
function and mechanisms involved in up-regulation of nestin in proliferation of 
progenitor cells is still unclear. One of the properties of nestin is that it cannot 
polymerize itself and co-polymerize with other intermediate filament proteins like 
vimentin, desmin and α-internexin (Sjöberg et al., 1994; Marvin et al., 1998; Eliasson et 
al., 1999). Phosphorylation and dephosphorylation of nestin may modulate assembly 
and disassembly of further intermediate filaments (Steinert et al., 1999) and these 
processes may play a significant role in increased cytoplasmic trafficking in 
stem/progenitor cells undergoing proliferation, migration and differentiation (Lendahl et 
al., 1990; Kachinsky et al., 1995; Vaittenen et al., 2001). In this context, we observed 
that nestin is associated with proliferating progenitor cells in vascular wall; therefore, it 
is thinkable that nestin in progenitor cells may participate in or promote the proliferation 
of progenitor cells. In agreement, our preliminary data using nestin siRNA transfected 
pulmonary arterial VSMCs provide evidence of inhibition of VSMC proliferation in the 
absence of nestin in vitro. Furthermore, nestin has been proposed to promote mesangial 
cell proliferation in vitro suggesting a supporting role of nestin in reparative action 
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against injury (Daniel et al., 2008). It has also been demonstrated that nestin is 
important for survival and self-renewal of neural stem cells (Park et al., 2010) Nestin 
might also play an anti-apoptotic function via Cdk5-induced phosphorylation of BCL-2 
that leads to inhibition of caspase-9 hence preventing the downstream caspase-3 
activation in rat vascular smooth muscle cells (Huang et al., 2009). In podocytes, nestin 
was suggested to protect from apoptosis by another mechanism i.e. by maintaining the 
regular arrangement of actin cytoskeleton in a rat puromycin aminonucleoside (PAN) 
induced model of nephrosis (Wen et al., 2011). Along with determining the fate of cells 
as stem/progenitor cells, nestin was suggested to play an important functional role in 
differentiation of pancreatic stem cells into insulin secreting cells (Kim et al., 2010). 
This process of differentiation did not take place in the absence of nestin. 
4.7 Mechanisms inducing nestin 
Similar to the functional role of nestin, mechanisms inducing or stimulating nestin 
expression are also a matter of debate. External stimuli may trigger nestin expression in 
certain cell types. In this context, hypoxia can be such one of such stimuli as used by us 
in one of the animal models that resulted in significant nestin up-regulation after 3 days 
of hypoxic exposure. In line with our observation, nestin is suggested to be induced by 
hypoxia in cochlear stem/progenitor cells in the inner ear (Chen et al., 2011) and Müller 
glial cells in adult rat retina (Xue et al., 2011). Hypoxia inducible factor-1 and HIF like 
factor (HLF) are known to act on their consensus enhancer element 5'-CACGTG-3', it 
was found that at least one such candidate site was present on the first intron of nestin. 
It is still to be examined whether a HIF/HLF-dependent expression of nestin exists and 
whether this candidate site could be involved (Sugawara et al., 2002). 
Similarly, extra-cellular soluble factors secreted by neighboring cells might also trigger 
gene expression; pulmonary artery fibroblasts were suggested to sense hypoxia and 
release soluble factors that stimulated pulmonary artery smooth muscle cell proliferation 
(Rose et al., 2002). Furthermore, proliferation of arterial smooth muscle cells could only 
occur when incubated with hypoxic endothelial cell conditioned medium suggesting the 
stimulation of vascular smooth muscle cell proliferation as a result of paracrine activity 
(Chanakira et al., 2012). 
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In conclusion, nestin expression was found in vasculature of lungs and nestin+ cells 
showed proliferation during development and vascular remodeling. Certain vascular 
wall cells capable of proliferation could be identified by nestin expression in lungs and 
may be used as prognostic and diagnostic markers and new target for therapeutic 
interventions of diseases like pulmonary hypertension. 
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5 Summary 
Vascular wall cells distinguished by expression of the neuronal stem cell marker nestin 
may represent stem cell-like progenitor cells for tissues in various organs. In one of our 
previous studies, we found that nestin expressing vascular smooth muscle cells and 
pericytes in testicular blood vessels are the progenitors of testosterone producing Leydig 
cells. The aim of this study was to investigate nestin expression and nestin+ cells in 
postnatal and adult lungs. 
To analyze the expression pattern of nestin and its role as marker for proliferating 
progenitor cells in the lung, nestin expression and localization was investigated during 
postnatal development and vascular remodeling in a hypoxia induced pulmonary 
hypertension model in mice. Nestin data was compared with expression of proliferation 
markers (PCNA, Ki67) and PDGF receptors. Nestin expression and localization was 
also investigated in two rat models of pulmonary hypertension, the monocrotaline 
model and the Su5416/hypoxia model (VEGF receptor-2 blockage by its antagonist 
Sugen 5416 in combination with hypoxia) as well as in human samples from patients 
suffering from pulmonary hypertension and pulmonary fibrosis.  
Nestin was found in a subpopulation of vascular smooth muscle cells in lung 
vasculature. As compared to adults, significantly higher nestin expression was observed 
in pulmonary vasculature of postnatal lungs. While investigating the time course of 
postnatal development, peaks of nestin expression and vascular smooth muscle cell 
proliferation were found from postnatal day 3 to day 10 that reduced gradually with no 
nestin and vascular smooth muscle cell proliferation in adults suggesting a strong 
correlation between nestin expression in and proliferation of vascular smooth muscle 
cells. Similarly, as compared to normoxic controls, in adult lungs nestin upregulation 
was found between 3 days and 1 week of hypoxic exposure but not at later time points 
when pulmonary hypertension became clinically and histologically evident. In hypoxic 
lungs peak of phosphorylated (activated) PDGF receptor-ß was observed between 4 
days and 1 week of hypoxic treatment. Nestin up-regulation correlated well with an 
increase of cell proliferation and PDGFR-ß phosphorylation/activation. 
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Higher nestin expression was also found in vasculature of lungs from monocrotaline 
and Su5416/hypoxia treated rat samples. In small arteries, nestin was found in vascular 
smooth muscle cells. In large arteries of lungs from both rat models, in addition to 
vascular smooth muscle cells, nestin was also found in cells present in so-called 
“vasculogenic zone” at the border of media and adventitia. In the Su5416/hypoxia 
model, nestin-positive vascular smooth muscle cells were also detected in more 
complex lesions with neointima, a characteristic feature of this model. Along with 
arteries, large veins of this model also showed strong nestin immunoreactivity and 
interestingly, nestin+ cells in these veins were found to be cardiomyocytes. 
In human samples from patients of pulmonary hypertension, nestin was found in 
vascular smooth muscle cells in small vessels, in “vasculogenic zone” in large vessels 
as well as in vascular lesions e.g. concentric lesions, plexiform lesions and 
recanalization of thrombosed arteries. In lung samples from patients of pulmonary 
fibrosis, nestin expression was predominantly found in vascular smooth muscle cells. 
Certain vascular wall cells capable of proliferation could be identified by nestin 
expression in lungs and may be used as prognostic and diagnostic markers and new 
target for therapeutic interventions of diseases like pulmonary hypertension. 
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6 Zusammenfassung 
Es wird vermutet, dass bestimmte Blutgefäßzellen, die sich durch die Expression des 
neuronalen Stammzellmarkers Nestin auszeichnen, als Vorläuferzellen für den Ersatz 
von geschädigtem Gewebe in verschiedenen Organen dienen können. So haben frühere 
Studien gezeigt, dass Nestin-exprimierende glatte Muskelzellen und Perizyten von 
Blutgefäßen des Hodens zur Neubildung von Leydigzellen in der Lage sind. Im Rahmen 
dieser Doktorarbeit sollte untersucht werden, welche Rolle Nestin-exprimierende 
Gefäßzellen in der Lunge während der postnatalen Entwicklung und unter 
pathologischen Bedingungen, z. B. den bei pulmonaler Hypertonie stattfindenden 
Umbauvorgängen der Gefäßwand (vaskuläres Remodeling), spielen. 
Immunhistochemische und Immunoblot-Analysen von Mauslungen sowie 
Untersuchungen an GFP-Nestin-Mäusen zeigten übereinstimmend eine dramatisch 
höhere Nestin-Expression während der frühen postnatalen Entwicklung als in der 
adulten Lunge. Interessanterweise konnte ein Maximum der Nestin-Expression 
zwischen Tag 3 und Tag 10 postnatal festgestellt werden. Die Nestin-exprimierenden 
Zellen wurden als eine Subpopulation der glatten Muskelzellen charakterisiert, die 
zudem durch die Expression von Proliferationsmarkern (PCNA, Ki67) gekennzeichnet 
sind. Die Studien deuten somit auf eine bisher nicht beschriebene Rolle von Nestin-
exprimierenden glatten Muskelzellen bei Proliferationsvorgängen während der 
postnatalen Lungenentwicklung hin.  
Für die Untersuchungen der Nestinexpression unter Bedingungen von pulmonaler 
Hypertonie wurden verschiedene Tiermodelle eingesetzt, bei denen das Krankheitsbild 
durch chronische Hypoxie (Maus) oder Monocrotalin (Ratte) induziert wird. Daneben 
konnten Lungen von Ratten genutzt werden, bei denen pulmonale Hypertonie durch 
eine Kombination von chronischer Hypoxie und Behandlung mit VEGF-Rezeptor2-
Antagonisten (Su5416) erzeugt wurde.  
Hypoxie induzierte eine starke Zunahme der Nestin-Proteinexpression in Mauslungen 3 
Tage nach Beginn der Behandlung, die nach weiteren 4 Tagen wieder zurückging. Die 
Zunahme der Nestin-Proteinexpression korrelierte mit einer Zunahme an 
Zellproliferation (PCNA/Ki67-positiven Zellen) und PDGF-Rezeptor β-Aktivität 
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(Phosphorylierung). Diese Studien weisen auf eine wesentliche und zeitlich definierbare 
Rolle von Nestin-exprimierenden glatten Muskelzellen beim Prozess des vaskulären 
Remodeling während der Entstehung von pulmonaler Hypertonie (volle Ausprägung 
nach 3 Wochen Hypoxie) hin.  
Vergleichbare Änderungen der Nestinexpression wurden auch in den beiden 
Rattenmodellen der pulmonalen Hypertonie gefunden. In kleinen Arterien war Nestin 
ausschließlich in glatten Gefäßmuskelzellen detektierbar. In großen Arterien konnte 
Nestin zusätzlich auch in Zellen der so genannten "vaskulogenen Zone" an der Grenze 
zwischen Media und Adventitia gefunden. Interessanterweise ließ sich im 
Su5416/Hypoxie-Modell Nestin auch in glatten Muskelzellen komplexer Läsionen mit 
Neointima und in großen Venen nachweisen. Deren nestinpositiven Zellen zeigten 
erstaunlicherweise die klassischen Merkmale von Kardiomyozyten.  
In menschlichen Proben von Patienten mit Lungenhypertonie wurde Nestin in glatten 
Gefäßmuskelzellen von kleinen Gefäßen, in vaskulogenen Zonen der großen Gefäße 
sowie an Stellen von Gefäßverletzungen (z. B. konzentrische Läsionen, plexiforme 
Läsionen) gefunden. In Lungenproben von Patienten mit Lungenfibrose war die  
Nestinexpression weitgehend auf glatte Gefäßmuskelzellen beschränkt. 
Die in dieser Arbeit erhaltenen Befunde  zur Rolle von Nestin-exprimierenden Zellen 
bei Proliferationsvorgängen in der Lunge unter pathophysiologischen Belastungen 
könnten von diagnostischem Nutzen sein und die Basis für neue therapeutische 
Optionen darstellen. 
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